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 ABSTRACT 
Colorectal cancer (CRC) is one of the most lethal malignancies, ranking second to 
lung cancer in males and breasts cancer in females. Its death rate has not significantly 
changed over the past 20 years in spite of surgical procedures that have vastly improved 
in the same period. This is likely due to the late stage at which CRC is diagnosed, and the 
intrinsically high, nonspecific toxicity that conventional chemotherapeutic treatments 
suffer from. 
Novel drug delivery strategies can be implemented to reduce the nonspecific 
toxicities of conventional chemotherapeutics. In such a strategy, a two-pronged approach 
to deliver therapeutic agents both locally and systemically may lead to a shift in the 
paradigm on the current treatment of CRC.  For the first approach, a colon-specific drug 
delivery system based on biodegradable hydrogels and novel linear polymeric carriers 
was designed. The second approach exploits the benefits of systemic delivery by utilizing 
a targeted polymeric carrier. 
For colon-specific drug delivery, interpenetrating network (IPN) hydrogels 
composed of pH-sensitive, aromatic azo group-containing hydrogels as one of its 
components, and a hydrolyzable network as the other were synthesized. The properties of 
IPNs were investigated with the aim of identification of structures suitable as colon-
specific drug delivery systems. The swelling kinetics for hydrogels with different 
compositions were determined at conditions mimicking the gastrointestinal tract. Also, 
iv 
physical properties of degradability and the modulus of elasticity in compression were 
used to characterize the properties of the IPN hydrogels. 
In the second study, three derivatives of the cyclic constrained nonapeptide 
specific to CRC, namely YW-KPIEDRPME (RPM1), methacryloylglycylglycine-6-
aminohexanoyl-8-amino-3,6-dioxaoctanoyl-8-amino-3,6-dioxaoctanoyl-8-amino-3,6-
dioxaoctanoyl-YW-KPIEDRPME (RPM2), and K(fluorescein)-KPIEDRPME (RPM3), 
were synthesized. RPM1 and RPM2 were incorporated into the water-soluble N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer.  
For the final study, two novel, linear polymeric systems were designed, one for 
systemic and the other for local delivery.  The former system was a carrier composed of 
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer, 9-aminocamptothecin (9-AC), 
and biorecognizable cyclic nonapeptide. In the latter system, a copolymer of HPMA and 
9-aminocamptothecin bound via an aromatic azo bond and a self-elimination spacer was 
synthesized. Therapeutic efficiency of a systemic versus local approach was evaluated in 
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BACKGROUND AND SIGNIFICANCE 
1.1. Colorectal Cancer 
Colorectal cancer (CRC) is one of the most lethal malignancies (1, 2), ranking second 
to lung cancer in males and breast cancer in females. The term colorectal cancer includes 
cancer of the colon, rectum, appendix, and anus. It has been shown that both genetic and 
environmental factors are leading causes implicated in the disease morphology (3). There 
were approximately 500,000 new cases diagnosed and 250,000 deaths recorded 
worldwide in 2000 (4). Factors that affect prognosis include the stage of the cancer, the 
blood levels of carcinoembryonic antigens (CEA), and the patient’s general health (5). 
The lifetime probability of developing colorectal cancer was estimated at 6.0 % for 
women, and 6.2 % for men (6).  
The pathologic stage is the most important determinant of prognosis. After 
diagnosis, five stages (0-IV) are used to assess the spreading of colon cancer cells within 
the colon or other parts of the body. In stage 0, the cancer cells have not spread to nearby 
tissues and there is no regional lymph node or distal metastasis. Treatment including local 
excision of the tumor with adjuvant therapy is given at this stage. In stage I, tumor has 
invaded submucosa but there is no regional lymph node or distal metastasis. Here, 
treatments include resection/anastomosis (removal of diseased tissue followed by the 
connection of healthy sections) of the diseased area. In stage II, tumor invades through 
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muscular layer into subserosa but there is again no regional lymph node or distal 
metastasis. Treatment includes resection/anastomosis followed by systemic treatment by 
chemo, radiation or biological therapy. In stage III, tumor cells have spread to organs and 
lymph nodes near the colon/rectum. The treatment is similar to that of stage II. Stage IV 
includes the spread of tumors cells to other parts of the body, such as liver or lungs. Here, 
treatment could include surgery for the removal of parts of the organ (like lung, liver, or 
ovaries) where the cancer may have spread, followed by the standard drug treatments (7). 
1.1.1. Current Screening Modalities 
Early diagnosis of colorectal cancer through screening can prevent most deaths (8, 
9) since the prognosis is heavily dependent on the stage of the disease. Screening 
involves the identification of neoplasms (which are cancerous precursor adenomatous 
polyps) in asymptomatic individuals (9). Identification and removal of such polyps 
(growth in the colon that projects from the lining of the intestine or rectum) can decrease 
cancer incidence and death (10, 11). It is well established that it is essential to screen for 
CRC in certain high-risk populations such as families with a history of familial 
adenomatous polyposis (FAP), and hereditary nonpolyposis colorectal cancer (HNPCC) 
(8). There are currently four predominant methods for the screening of colorectal cancer 
(12), Fecal Occult Blood Test (FOBT) (13-15), Flexible Sigmoidoscopy (16, 17), Double 
Contrast Barium Enema (DCBE) (18-20), and Colonoscopy (21). 
  Fecal Occult Blood Testing (FOBT) is the most common screening modality used 
in the United States (22). This test is based on detecting the level of hemoglobin in the 
stool. It is conducted with a guaiac-impregnated card (a paper surface that has a phenolic 
compound, alpha-guaiaconic acid) that turns blue in the presence of peroxidase-like 
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substances, such as heme (23). The hemoccult test can detect about 20 ml of blood loss 
per day in 80-90% of patients and 10 ml of blood loss per day in 67 % (15). For a single 
test, three separate stool samples collected on consecutive days are tested. However, this 
technique has a major disadvantage in its low sensitivity (more than 40 % of cancers will 
be missed by this technique) (24). Sigmodoscopy has high sensitivity and specificity in 
CRC detection for the distal colon. This method can reduce mortality caused by rectal 
cancer and distal colon tumors in patients who have undergone the test (25). The 
technique is limited by its low sensitivity for lesions beyond the reach of the instruments, 
which constitutes about half of all colorectal neoplasms (22). Colonoscopy, on the other 
hand, allows direct visualization of the entire colon and the detection of adenomas with 
high sensitivity. This technique provides the opportunity for direct removal of adenomas 
and samples for biopsies of suspicious lesions can be removed. This procedure can 
decrease mortality by up to 70%, and is currently the most sensitive method for detecting 
CRC. Finally, Double Contrast Barium Enema (DCBE) allows examination of the entire 
colon and is relatively inexpensive (26). This technique is inferior to colonoscopy for the 
detection of polyps. When comparing DCBE against colonoscopy examination, DCBE 
detected only 39 % of all adenomas. This uncomfortable procedure also renders it not 
patient compliant. On a positive test, DCBE has to be also followed by colonoscopy, 
which has reduced the utility of DCBE for CRC screening.  
1.1.2. Current Treatment Options 
The treatment of CRC predominantly involves the surgical removal of the right or 
left side of the colon (hemicolectomy). This is the principal treatment for colorectal 
cancer and the only treatment that can cure the patient. The cure rate of patients 
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undergoing hemicolectomy for adenocarcinoma removal is only 50%, depending on the 
tumor grade, stage, and the presence of vascular or lymphatic invasion (27, 28).  Local 
recurrence rates vary from 4% to 54%, which are directly correlated with rates of 
survival.  Newer surgical procedures such as laparoscopic resection are being evaluated 
for colorectal tumor removal. These techniques significantly improve the quality of life 
of patients by reducing postoperative morbidity.  Recurrence after colon cancer surgery, 
predominantly involves the liver, which is the sole metastatic site in 30 % of patients 
(29). These relapsed tumors are treated with systemic low molecular weight 
chemotherapeutics. These therapies are effective in prolonging time to disease 
progression, but the percentage of overall survival is still quite low (30). The major 
hurdle for adjuvant chemotherapy is its indiscriminate uptake into normal tissues, which 
can result in severe toxicities, including nausea, vomiting, diarrhea, mucositis, 
myelosuppression, and cardiac and neurologic effects, thereby limiting its therapeutic 
efficacy. Hence, novel strategies are being developed to optimize drug delivery to the site 
of action.  
1.1.3. Chemotherapeutics of Colorectal Cancer Treatment 
Surgery is an integral part in the treatment of CRC and the extent of surgery for 
treatment has undergone constant modification (31). Only 50% of patients undergoing 
treatment for rectal adenocarcinoma can be cured and surgery remains the principal tool. 
While a large number of patients with colon cancer will have potentially curative 
resection after surgery, a significant number will develop recurrence. Without surgery, 
the median survival in patients with hepatic metastatic disease is 4.5 months. 
Chemotherapy is thus used as supportive care for treatment of disease. It has been 
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demonstrated that chemotherapy is effective in prolonging time to disease progression 
and overall survival (32). For tumors at distant sites like lungs and bone, systemic 
chemotherapy is used whereas for local relapse, local radiotherapy is more appropriate.  
5-Fluorouracil (5-FU) is a prodrug which inhibits thymidylate synthase. 5-FU has 
been used for the treatment of colorectal cancer for the past 40 years. The plasma half-life 
of 5-FU is very short (about 8-14 min); for this reason, prolonged infusional therapy is 
preferred to a bolus therapy. It has been demonstrated that 5-FU alone as a single agent 
has a response rate of about 11% and a median survival of 11 months in those with 
advanced disease (33). Traditionally, chemotherapy has been given intravenously as this 
route has more predictable plasma concentration. Comparable efficacy and median 
survival by the use of intravenous 5-FU and an oral formulation have been shown (34, 
35). The toxicity profiles were similar, with greater hand-foot syndrome and less 
mucositis, neutropenia, and alopecia in the oral treatment. New chemotherapeutic agents 
with mechanistically novel modes of action are also being developed. Irinotecan® is a 
topoisomerase I inhibitor that blocks cell division by inducing single-strand DNA breaks. 
This drug has been shown to have a response rate of 11-23 % in patients with 5-FU 
resistance and advanced CRC (36, 37). Oxaliplatin® is a third-generation platinum 
analogue that produces DNA cross-linkages and apoptotic cell death. Studies have shown 
response rates of 46 % of 5-FU plus oxaliplatin versus 10% with oxaliplatin alone (38). 
Clearly, with novel approaches enhanced, response rates can be achieved. 
1.1.4. Camptothecins 
Camptothecin (CPT) is a specific topoisomerase I inhibitor discovered in the 
1960s  is a naturally occurring alkaloid (39). It was first extracted from the stem wood of 
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the Chinese tree Camptotheca acuminata while screening thousands of plants in search of 
steroids. The tree extract showed significant antitumor activity in standard in vivo cell 
culture and preliminary animal model (induced with tumors). During Phase I and Phase II 
clinical trials, it showed strong antitumor activity among patients with gastrointestinal 
cancers, though it caused severe side effects, with the most severe being myelosupression 
and haemorrhagic cystitis. These side effects eventually resulted in the suspension of 
Phase II trials in 1972. 
The early mechanism of action of camptothecin suggested that cytotoxicity might 
result from inhibition for DNA and RNA synthesis, and it was concentration dependent 
(40-43).  
Another mechanism of action was discovered in the late 1980s. It was identified 
as an unequivocal inhibitor of topoisomerase I (44, 45). This sparked a new wave of 
interest in developing novel derivatives which could be given as combination 
chemotherapeutic, as it presented a novel mode of action.  During its early revival, it was 
observed that the open lactone ring of camptothecin is a much less potent antitumor agent 
with severe adverse effects (46). Hence, several camptothecin derivatives with an intact 
lactone ring were synthesized. Within these series of compounds, two CPT analogs (Fig. 
1.1) have been approved and are used in cancer chemotherapy today, topotecan® and 
irinotecan® (47-49).  
Significant improvement of survival was demonstrated with CPT analogs 
topotecan and irinotecan; however, patients still suffer from myelosupression, 
neutropenia, anemia and diarrhea and these appear to be dose-limiting factors for these 
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compounds. There is great interest in the design of a new generation of camptothecins 
that exert strong topoisomerase I inhibitory activity with a good toxicity profile.  
1.2. Biodegradable Hydrogels as Drug Delivery System 
Hydrogels are three-dimensional networks of hydrophilic polymer chains that are 
water-insoluble. Due to the presence of physical or chemical crosslinks they can absorb 
large amounts of water without dissolving, hydrogels (50) have been extremely useful as 
biomaterials. Their uses have been proposed for a wide range of biomedical and 
pharmaceutical applications. Applications, including drug delivery (51-53), tissue 
engineering (54-56)  and contact lens design (57, 58), have widely adapted the use of 
these gels. Hydrogels used as drug delivery systems are typically polymers or copolymers 
from among poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA) (59),  
poly(hydroxyethyl methacrylate) (PHEMA), poly(vinyl alcohol) (PVA), polyurethane 
(PU), and poly(ethylene oxide) (PEO) (60). One of the most widely used hydrogels as 
novel material is based on poly(hydroxyethyl metacrylate) (PHEMA) (61, 62). 
Copolymer of (2-hydroxyethyl) methacrylate (HEMA) and ethyleneglycol dimethacrylate 
(EGDMA) (Fig. 1.2.) results in a crosslinked hydrogel structure which has been used for 
the production of soft contact lenses and as reservoirs for drug delivery (63). Hydrogels 
have been synthesized by three main synthetic processes, namely, a) crosslinking 
polymerization, b) formation of crosslinks with existing polymer chains and c) joining of 
active chain ends into crosslinks (end-linked networks). The typical parameters used to 
characterize hydrogels networks include polymer volume fraction in the swollen state 
(ν2,s), the molecular weight of the polymer chain between two neighboring crosslinking 





Figure 1.1. Chemical structure of camptothecin and camptothecin analogues that are 






















retained by the hydrogel in the swollen state is a measure of the polymer volume fraction. 
The degree of crosslinking of a polymer network can be characterized by the molecular 
weight between two consecutive crosslinks (which can be formed physically or 
chemically). Finally, the mesh size provides a measure of space available between the 
macromolecular chains. These parameters can be determined theoretically or through the 
use of a variety of experimental techniques. Two techniques which are utilized to 
elucidate the structure of hydrogels are equilibrium-swelling theory (65) and statistical 
branching theory (66). 
The equilibrium swelling of polymer gels is often described in terms of the Flory-
Rehner theory, which describes the forces at play when a crosslinked network is 
immersed in a fluid and allowing the system to reach equilibrium.  This force can be 
written in terms of Gibbs free energy Eq. (1), the thermodynamic force of mixing and the 
retractive force of the polymer chains. 
 
∆G୘୭୲ୟ୪ ൌ ∆Gୣ୪ୟୱ୲୧ୡ ൅	∆G୫୧୶୧୬୥		ሺ1ሻ 
Here, the ΔGmixing is a measure of the Gibbs free energy change due to the mixing of a 
polymer with a solvent, and ΔGelastic is the contribution of the forces involved in the 
deformation of the crosslinked network elastically. 
The statistical branching theory, as described by Dušek et al. (66-69), is a Markov 
process that models a polymer structure in which each individual in generation n 
produces some random number of individuals in generation n + 1, according to a fixed 
probability distribution that does not vary from individual to individual. Statistical 
theories have been used frequently in crosslinking studies due to their ability to explain 
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complex chemical systems in a simpler manner. Analysis of a statistical network using 
the 1st-order Markov process is described below (adapted from (70)). The probability of 
bond formation of a given type depends only on the states of units the bond connects. The 
probability that the selected unit A in state i extends a bond to unit B in state j by reaction 
of groups p and r, respectively, is written as  






Very often, less precise specifications of transition probabilities are used and the states of 
units A and B are disregarded 




In a number of instances, units A bear groups a and units B bear groups b. Then, relation 
(3) is simplified to  
݌஺௔→௕௑ ≡ ݌஺௔௕஻		≡௉ಲಳ௔௡ௗ௣ಲಲା௉ಲಳୀଵ		  
஻ܲ஺ ൅ ݌஻஻ ൌ 1 
For only A and B units having, respectively, groups a and b, when only bonds a-b are 
݌஺௔→௕஻ ≡ ݌஺௔௕஻		≡௉ಲಳୀଵ		  
஺ܲ஻ ൌ 1		ሺ5ሻ 
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In this simplest case, the fraction of reacted groups engaged in bonds a-b is equal to 
αApAB=αA. The nature of statistical generation of a branched structure can also be further 
analyzed using branching theories (71-74).  
1.2.1. Stimuli Responsive Materials 
Stimuli responsive hydrogels that exhibit swelling behavior dependent on the 
external environment are of great interest in the biomedical field. These gels can be 
tailored to dynamic change their swelling ratio depending on the stimuli. Various stimuli 
can be used to modulate the swelling ratio like external pH (75, 76), temperature (77, 78), 
and ionic strength of the local environment. pH-responsive materials are of great 
importance because they can be customized to exploit their physical property.  
Hydrogels which exhibit pH-dependent swelling behavior contain a pendant 
ionizable group (either acidic or basic pendant groups). In aqueous media of appropriate 
pH and ionic strength, the pendent groups can ionize, developing fixed charges on the 
gel.  Hence, these materials attract the most interest as they hold great potential in drug 
delivery applications.  One example of pH-sensitive systems used in drug delivery is a 
system developed by Ishihara et al. (79). They combined a pH-sensitive hydrogel with 
glucose oxidase enzyme to regulate insulin release. This system was based on the fact 
that when glucose entered the hydrogel, glucose oxidase enzyme would convert glucose 
to gluconic acid, thereby reducing the pH and ionizing the pendent side chains. The 
ionization would cause charge repulsion, thereby expanding the gel and releasing the 
insulin.  
Currently, hydrogels suitable for colon-specific delivery have received 
considerable interest as they afford the release of therapeutics locally (80). While one 
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approach, pioneered by Saffran (81), relies on hydrogels containing aromatic azobonds in 
the crosslinks (82-84), another approach is based on polysaccharide drug delivery 
systems (85). The colon-specificity in both designs relies on the specificity of bacterial 
enzymatic systems and on the physicochemical properties of the hydrogels. The 
degradability of hydrogels depends strongly on the equilibrium degree of swelling (86, 
87). The high degree of swelling of colon-specific hydrogels is usually based on an 
ionizable comonomer-containing COOH group (88). The ionizable COOH groups 
deprotonate immediately after they reach the small intestine, followed by a rapid increase 
in the degree of swelling due to an increase in osmotic pressure, which modulates the 
expansion of the polymer chains. To achieve high rates of degradation, hydrogels with a 
large equilibrium degree of swelling have to be used.  
Brøndsted et al. (89, 90) designed a novel hydrogel that contained both acidic 
comonomer and degradable azoaromatic cross-links. Radical polymerization of acrylic 
acid, n-tert-butylacrylamide, and N-methacrylamide crosslinked with 4,4’-di-
(methacryloylamino)-azobenzene was used for synthesis. They found that the crosslinks 
were degradable by microbial azoreductase present predominantly in the colon, but the 
degradability in vitro was found to be related to the degree of swelling, and the structure 
and length of the crosslinking agent.  
The structure of the azoaromatic crosslinks was further modified by Yeh et al. 
(87). Here, N,N-dimethylacrylamide copolymers precursors were crosslinked with N,N’-
ε-aminocaproyl)-4,4’-diaminoazobenzene (Fig. 1.3). The degradability of hydrogels 
synthesized by two different methods, crosslinking of polymeric precursors and 




















hydrogels prepared by crosslinking of polymeric precursors was faster than that of 
hydrogels prepared by crosslinking copolymerization. The differences in the gel 
degradation pattern and the cleavage rate of azo bonds were attributed to the differences 
in the structure of the hydrogel network, i.e., the molecular weight of primary chains and 
the formation of chain entanglements. 
To further control the kinetics of swelling of pH sensitive azoaromatic crosslinked 
hydrogels, Akala et al. (76) introduced a hydrolyzable comonomer in the network 
structure. Hence, the hydrogels contained two types of crosslinking agents, one 
hydrolyzable, the other enzymatically degradable.  The hydrolyzable crosslinking agent 
was based on N-alkanoyl, O-acylhydroxylamine moieties.  They studied the dependence 
on the length of the alkyl chain of the hydrolyzable comonomer on the rate of hydrolysis. 
Their studies indicated that the introduction of N,O-disubstituted hydroxylamine moieties 
into crosslinks of hydrogels produced structures whose kinetics of swelling at neutral pH 
can be controlled.  
1.2.2. Interpenetrating Polymer Networks 
Interpenetrating networks (IPNs) are binary systems composed of two mixed 
polymers, each of which is individually crosslinked (Fig. 1.4) (91).  Adjustable  
swelling kinetics can be achieved with these systems. By combining two different 
systems, unique properties can be achieved with these biomaterials (92). For example, 
combinations of pH- and temperature-sensitive polymers (93) and polymers forming 
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networks, IPN hydrogels may have stronger mechanical properties due to the physical 
entanglements and network interactions. 
There are two main synthetic processes to synthesize IPNs. The former is 
prepared by sequential IPN synthesis technique and the latter by a simultaneous 
interpenetrating networks (SINs) formation.  Sequential IPNs are formed by 
polymerizing the first network (which contains monomer, crosslinking agent, and 
initiator), which is then swollen with the second combination of monomers and 
crosslinking agent, and then polymerized to form an IPN structure (Fig. 1.5).  The latter 
technique involves the synthesis of IPN by two different polymerization techniques (for 
example, free radical and condensation reaction). Hence, IPN can be formed from two 
different monomer and crosslinking agent pairs together in one step. IPNs can be further 
classified by their structure, which can be full-IPNs or semi-IPNs. These two distinctions 
come from the fact that full IPNs are completely interlocked, thus generating a lot of 
entanglements and interaction between the networks. In the case of full IPNs, one 
network cannot be removed from another without chemical linkages being broken. Semi- 
IPNs involve a network where only one component is three-dimensional, and the other 
has a linear structure. The linear component can interact with the first network and 
change its physical properties. These sorts of systems are unique in that the linear 
component of the IPN can be removed from the network if the material is swollen in the 
appropriate solvent. 
1.3. Polymeric Carriers for Systemic Delivery 
The use of hydrophilic polymers as drug delivery vehicles is well accepted and 













incorporated in polymeric carriers have various advantages (when compared to low-
molecular weight drugs), including long-lasting circulation in the bloodstream, decreased 
nonspecific  toxicity of the conjugated drug, increased solubility of hydrophobic 
compounds, decreased immunogenicity of the targeting moiety (96, 97), and the 
modulation of the cell signaling and apoptotic pathways (98, 99).  An assortment of 
polymeric carriers are currently being developed, including liposomes (100, 101), 
polymeric  nanoparticles (102), micelles (103, 104), and dendrimers (105).   
Macromolecules afford the advantage of nonspecific accumulation inside solid 
tumors (Fig. 1.6). This phenomenon is due to the so-called Enhanced Permeability and 
Retention (EPR) effect (106). This effect is based on the fact that vasculature of normal 
and diseased tissue is vastly different; the latter have leaky vasculature which increases 
their permeability and, coupled with their poor lymphatic drainage, leads to the 
preferential extravasation and retention of macromolecules.  
After the localization of macromolecules into a solid tumor, they have to be 
internalized and then release their cargo. The entry of macromolecules into the cell is 
through endocytosis.  After internalization of particles, the contents are trapped in the 
endosome. Then, in a subsequent step, the endosome is fused with lysosome. The 
lysosome contains hydrolytic enzymes which are encompassed in an acidic environment. 
All endocytosed nanoparticles will be finally localized in this compartment (107). The 
lysosomal compartment is permeable only to small hydrophobic molecules. Hence, any 
drug attached to the polymeric carrier must be released before it is therapeutically 








Figure 1.6. The enhanced permeability and retention (EPR) effect of macromolecules 










Oligopeptides spacers with the sequence glycylphenylalanylleucylglycyl (GFLG) have 
been extensively used for this purpose (108, 109).  Other spacers which are acid sensitive 
can also be employed, like acetals, cis-aconityl, and hydrazone (110, 111). 
 Various strategies are being developed for the delivery of camptothecins, 
including conjugation to polymers to improve solubility and reduce nonspecific toxicity 
(112-114). Berrada et al. (115) designed a novel biodegradable and biocompatible 
injectable thermogelling drug delivery system based on chitosan polymers. The addition 
of glycerol-2-phosphate (β-GP) to the polymer solution induces a sol-gel transition at 
physiological temperature. When injected, this vehicle flows to fill voids within a cavity 
and becomes a solid at physiological temperature. The chitosan used in this study showed 
degradation in vivo in 6 months.  
In their study (Berrada et al. (115)), they designed a system such that the 
anticancer drug camptothecin was homogenously dispersed within the chitosan hydrogel. 
Drug encapsulated within the gel is released due to the swelling, diffusion, and 
degradation of the matrix. This delivery system was then implanted intratumorally into a 
subcutaneous mouse tumor model. The effectiveness of this novel delivery system was 
measured in terms of tumor growth delay. The polymeric implant had delayed tumor 
growth over a long period of time (approximately 30 days), as compared to free drug 
given systemically (8 days) at the same dose.  Controlled local delivery was also shown 
to have lower systemic toxicity as compared to the free drug. Finally, the increased 
therapeutic efficacy of their hydrogel system was attributed due to the extended 
controlled release of the therapeutics. 
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A different strategy proposed by Caiolfa et al. (117) involved the covalent 
attachment of camptothecin to a polymer carrier. In their study, N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer was synthesized containing 5 and 10 
wt % camptothecin (CPT). CPT was attached to the polymeric backbone via a Gly-Phe-
Leu-Gly spacer. This spacer afforded the release of unmodified drug by esterolytic and 
proteolytic activity. The conjugated drug was fairly stable in buffer solution at neutral pH 
with a hydrolysis rate of 0.2-0.4 % free CPT/h.  Attachment of CPT to the polymeric 
carrier changes the biodistribution of the parent compound with higher accumulation at 
the tumor site.  A cumulative dose of 60 mg/kg had a 90 % tumor growth inhibition when 
incorporated in the polymeric construct without inducing any toxic side effects. On the 
other hand, free drug of a cumulative dose of 60 mg/kg administered i.v. as 
12.5mg/kg/day had induced 5/7 toxic deaths. It was clearly shown that tumor 
accumulation and retention plays a key role in the pharmacology of the conjugates in 
terms of higher tolerability and enhanced potency.  
1.3.1. Targeted Polymeric Carrier for Colorectal Cancer 
Anticancer drugs intrinsically suffer from high toxicity, which limits their dosage 
and effectiveness in a clinic setting. Polymeric systems in general afford the advantage of 
improving drug solubility, increasing stability, enhanced tumor accumulation, and 
sustained release when compared to free drug. By implementing these strategies, the 
therapeutic window of potent and toxic drugs can be increased. A drawback of these 
delivery systems is that although enhanced tumor accumulation occurs, there is still a 
significant amount of drug not reaching the tumor.  
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Another drawback of conventional polymeric delivery systems relates to the slow 
rate of internalization after passive targeting to tumor tissue through the endocytic 
pathway.  Hence, there is an immense interest in designing a new generation of 
molecularly targeted therapeutics through tumor-specific mAbs or ligands that bind to 
receptors present on tumor cells. Development of these systems can potentially lead to a 
higher local concentration and enhance tumor cytotoxicity as compared to its untargeted 
counterpart. Furthermore, targeted therapeutics may change the mechanism of cell entry 
from fluid phase pinocytosis to receptor-mediated endocytosis. The latter mode of entry 
results in a faster rate of internalization when compared to fluid phase (nontargeted 
systems) uptake (118) and is thus more efficient. Numerous antibodies (119, 120) and 
peptides (121-124) have been developed to target colon cancer. The most interesting 
targeting agent for colorectal cancers is based on peptide sequences. Combinatorial 
peptide library techniques have accelerated the identification of targeting peptides and 
stimulated their application due to their ease of synthesis, low immunogenicity, and 
desirable pharmacokinetic properties.  Two of the most promising sequences found in the 
literature are the HEWSYLAPYPWF (124) sequence targeted to WiDr cells and the 
nonapeptide, CPIEDRPMC, derived from a disulfide constrained CX7C library and 
shown to bind specifically to poorly differentiated colon carcinoma cells (HT-29) (121).  
Kelly et al. (121) used bacteriophage-derived libraries to select peptides binding to colon 
cancer cells.  They used a subtraction method to distinguish between well-differentiated 
HCT116 and poorly differentiated HT29 colon carcinoma cells.  Utilizing this method 
yielded peptides that displayed a consensus RPM sequence motif, which mediated 
preferential binding to HT29 cells. This peptide sequence was then further modified to 
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carry an imaging agent for real-time endoscopic tumor detection in a murine model (125). 
The modified peptide had a 24-min blood half-life, and the tumoral accumulation was 
6.9% of injected dose/g, approximately 7-fold higher than a scrambled control peptide. 
They also observed that orthotopic colonic tumors (HT29) were readily detectable by 
fluorescence endoscopy even when tumors were submucosal. 
1.4. Polymeric Carriers for Local Delivery 
The oral route is the preferred manner of administration for most drugs. It is well 
known that there in an increased tight junction (TJ) permeability of macromolecules in 
epithelial cancers (126). This macromolecular permeability has been shown to be also 
present in polyps their TJs are leaky, allowing the uptake of high molecular weight dyes 
(127, 128). This serendipitous phenomenon (enhanced permeability of macromolecules) 
can be exploited by novel drug delivery design. Specific targeting of drugs to the colon is 
recognized to have several therapeutic advantages. Molecules that are susceptible to be 
destroyed by the acidic environment of the stomach or metabolized by pancreatic 
enzymes are only slightly affected in the colon. Treatment of colonic diseases such as 
colorectal cancer is more effective with the direct delivery of drugs to the colon (80). 
This sort of treatment will maximize the effectiveness of the drug. There is an increased 
interest in the design and synthesis of nanomedicine technology for colon-specific 
delivery.  
Patients with relapsed CRC predominantly have disease confined to the liver, and 
their blood supply derived from the portal vein. A study performed with six randomized 
trials of hepatic arterial infusion demonstrated response rate of 41 % compared with 14% 
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for systemic therapy (129). Hence, targeting of drugs specifically to the colon using new 
and improved delivery strategies could provide significant clinical benefits.  
One approach to target polymer-bound drug to the colon is by choosing the 
appropriate spacer. Spacers containing aromatic azobonds in the side chain are frequency 
employed for this purpose (130-132). After selectively targeting the macromolecule to 
the colon, the unmodified drug can be released at the site of action (133).  
Local delivery of cyclosporin A can be effective in treatment of inflammatory 
bowel disease (IBD).  Hence, Lu et al. (134) conjugated cyclosporin A to N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer via an aromatic azo bond, which can 
be specifically cleaved by azoreductase activity in colon. The cleavage of the aromatic 
azo bond was monitored in vitro, results indicated that the free drug was released due to 
azoreductase activity and the conjugates were resistant to endopeptidase activity. 
Sakuma et al. (133) synthesized N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymer conjugates containing 9-aminocamptothecin (9-AC) to the side chain. Here, 9-
AC was bound via spacers containing amino acid residues (leucylalanine or alanine)  and 
aromatic azo bonds. Their studies indicated that the azo bond was reduced first, 
generating a peptide-9-AC intermediate. In a subsequent step, cleavage of the peptide 
bond by peptidase activity released the unmodified 9-AC. They also found that the 
degradation of peptide bonds and release of unmodified 9-AC depended strongly on the 
chemical structure of the spacer between the drug and the azo residue.  The researchers 
also found changing the peptide spacer from Ala to Leu-Ala resulted in a dramatic 
change in the degradation profile. The amino acid 9-AC conjugate was only negligible 
cleaved, whereas an oligopeptide spacer containing 9-AC showed complete release. 
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These data nevertheless did not translate to optimum in vivo results (135). The release 
rate from the conjugate was not fast enough to achieve high colon concentrations of free 
9-AC when tested in rats. Hence, a second generation of 9-aminocamptothecin bound via 
an aromatic azo bond and a self-elimination spacer was synthesized by Gao et al. (132) 
(Fig. 1.7). Their results indicated a fast and highly efficient release of unmodified 9-AC 
from the polymer in the colon after azo bond cleavage. The novel aromatic azo bond 
spacers presented here have a potential for colon-specific drug delivery. 
1.5. Statement of Objectives 
The objective of this project is to design and synthesize novel drug delivery 
systems that can be implemented to reduce the nonspecific toxicities of conventional 
chemotherapeutics. To achieve this goal, we utilized a two-pronged approach to deliver 
therapeutic agents both locally and systemically. This may lead to a shift in the paradigm 
on the current treatment of CRC.  For the first approach, a colon-specific drug delivery 
system based on biodegradable hydrogels and novel linear polymeric carriers was 
designed. The second approach exploits the benefits of systemic delivery by utilizing a 
targeted polymeric carrier.  
Novel drug delivery strategies can be implemented to reduce the nonspecific 
toxicities of conventional chemotherapeutics. In such a strategy, a two-pronged approach 
to deliver therapeutic agent both locally and systemically may lead to a shift in the 
paradigm on the current treatment of CRC.  To design such a system, three specific aims 
were proposed: 
1) For colon-specific drug delivery, interpenetrating network (IPN) hydrogels 














its components, and a hydrolyzable network as the other will be synthesized 
and the relationship between their structure and properties will be evaluated 
(addressed in Chapter 2). 
2) Design a new generation of cellular targeted therapeutics that binds to 
receptors that are present on colonic tumor cells. The impact of the structure 
of the HPMA copolymer-peptide conjugates on the biorecognition by poorly 
differentiated HT-29 colon carcinoma cells will be investigated (addressed in 
Chapter 3). 
3) Two linear polymeric-systems will be designed, one for systemic and the 
other for local delivery. Therapeutic efficiency of a systemic versus local 
approach will evaluated in vivo using a noninvasive bioluminescence imaging 
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SYNTHESIS AND CHARACTERIZATION OF NOVEL  
AROMATIC AZO BOND-CONTAINING PH-  
SENSITIVE AND HYDROLYTICALLY  
CLEAVABLE IPN HYDROGELS 
2.1 Abstract 
Novel interpenetrating network (IPN) hydrogels, composed of a pH-sensitive, 
aromatic azo group-containing network as one component (Network A), and a 
hydrolyzable network as the other (Network B) were prepared by a sequential process.  
The first network was formed by crosslinking of a reactive polymer precursor (copolymer 
of N,N-dimethylacrylamide, acrylic acid, N-tert.butylacrylamide, and N-methacryloyl-
glycylglycine p-nitrophenyl ester) with an aromatic azo group containing diamine ((N,N’-
ε-aminocaproyl)-4,4’-diaminoazobenzene).  The second network was formed by radical 
crosslinking copolymerization of N-(2-hydroxypropyl)methacrylamide with N,O-
dimethacryloylhydroxylamine.  Hydrogels synthesized in this manner were homogeneous 
and showed no evidence of phase separation. The composition of the hydrogels was 
manipulated to determine the influence of hydrogel composition on the equilibrium 
degree of swelling, modulus of elasticity in compression, and on the rate of degradation 
of Network B.  To mimic the conditions in the gastrointestinal tract, properties of the 
hydrogels were evaluated after abrupt change of pH from pH 2.0 to pH 7.4. The analysis 
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of IPN structure revealed that crosslinking efficiency of radically polymerized Network B 
(10-30%) was lower than that of step polyaddition Network A.  In the IPN gels, the 
crosslinking efficiency was even lower and was close to 10%.  Factors contributing to the 
low crosslinking efficiency of IPN include higher dilution at network formation and 
possible negative effect of the components of Network A on radical polymerization of 
Network B.  The major advantage of IPN hydrogels, when compared to traditional pH-
sensitive networks, is the linear swelling profile following abrupt change of pH from 2 to 
7.4.  This indicates the suitability of IPN as carriers for oral drug delivery. 
2.2 Introduction 
Oral delivery of peptides and proteins is an attractive therapeutic modality for 
chronic dosage in non-life-threatening disorders (1). The major problem associated with 
oral delivery of proteins and peptides is their degradation in the stomach and small 
intestine due to the high proteolytic activity present at these sites (2). To circumvent this 
problem, delivery of proteins and peptides to the colon is very desirable (3). The colon 
has low enzymatic activity and is a less hostile environment for protein delivery.  Many 
attempts have been made by various groups to take advantage of colon-specific delivery 
using elaborate techniques such as nano-particulate carriers for the colonic mucosa (4), 
pressure-controlled colon delivery devices (5), and employing of enteric coatings (6). 
However, the major obstacle with all these techniques is associated with the colonic 
variation among different individuals and the transient variation of the local colonic 
region. 
Aromatic azo bond-containing pH-sensitive hydrogels have been extensively 
studied as carriers for colon-specific delivery (7, 8).  Due to the presence of carboxylic 
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groups in their structure, such hydrogels are compact at lower pH but swell as pH 
increases.  Once inside the colon, highly swollen aromatic azo bond-containing hydrogels 
become accessible to azoreductase activities; this results in the reduction of the azo bond 
and degradation of the hydrogel matrix. The major drawbacks of these hydrogels are their 
swelling properties; a large burst effect occurs when the pH is changed from below to 
above its pKa and the swelling equilibrium is rapidly reached. This burst can cause the 
cargo present within the gel to be prematurely released in the small intestine. Many 
structural modifications have been attempted, for example the incorporation of 
hydrolyzable side-chains, with modest success (9).   
Interpenetrating network hydrogels (IPN) consist of two independently 
crosslinked networks that are interlocked (10). Unique properties can be achieved with 
these biomaterials (11). For example, combinations of pH- and temperature-sensitive 
polymers (12) and polymers forming polyelectrolyte complexes (13) have been 
investigated.  IPN hydrogels may have more favorable mechanical properties due to the 
physical entanglements and network interactions, when compared to individual 
crosslinked networks.  
A novel approach to form IPN hydrogels, presented here, is the combination of a 
pH-sensitive network and a hydrolyzable network.  IPN hydrogels that contained pH- 
sensitive subunits (acrylic acid) which were crosslinked with an aromatic azo bond were 
synthesized.  Such hydrogels would be in a contracted state at the low pH of the stomach 
and they would start swelling at a higher pH in the intestine.  It is well accepted that the 
equilibrium degree of swelling influences the degradation rate of the gel network (14, 
15).  If one assumes that the transit time to the colon from the stomach is approximately 6 
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h, then the hydrogel should be in the fully swollen state after this time period to provide 
degradability in the colon.  To manipulate the swelling kinetics of the pH-sensitive 
network, we introduced a biodegradable crosslinking agent, (N,O-
dimethacryloylhydroxylamine (DMHA) into one of the networks (16).  A poly(N-(2-
hydroxypropyl)methacrylamide) (PHPMA) network, crosslinked with DMHA, could be 
hydrolyzed at pH above 7 by undergoing a Lossen rearrangement (17), resulting in the 
formation of a polymer-bound carboxyl and amino group with concomitant release of 
carbon dioxide. The attempt of this study was to investigate the properties that would 
influence the swelling profile of IPN hydrogels.  The relationship between the structure 
of individual networks and the properties of the IPN hydrogels has been evaluated. 
To this end, Networks A and B were prepared separately, and homogeneous IPN 
hydrogels were prepared by a sequential process.  Network A was prepared by the 
crosslinking of a reactive polymer precursor (copolymer of N,N-dimethylacrylamide 
(DMAA, to increase biocompatibility), acrylic acid (AA, pH-sensitive monomer), N-
tert.butylacrylamide (BuAA, to improve mechanical properties), and N-
methacryloylglycylglycine p-nitrophenyl ester (MA-GG-ONp, introduces reactive ester 
groups for crosslinking) with an aromatic azo group-containing diamine, N,N’-(ε-
aminocaproyl)-4,4’diaminoazobenzene (NH2-R-AZO-R-NH2). Network B was prepared 
by crosslinking copolymerization of N-(2-hydroxypropyl)methacrylamide (HPMA) and 
the crosslinker DMHA.  Modeling of network structure for both IPN and individual 
networks was accomplished using a statistical branching theory.  The theoretical values 
and experimental data were compared and the impact of the composition of individual 
networks on the structure of IPNs was evaluated. 
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2.3 Materials and Methods 
2.3.1 Chemicals 
NH2-R-AZO-R-NH2 (18), HPMA (19), DMHA (16), and MA-GG-ONp (20) were 
synthesized as described previously.  Solvents and reagents used for synthesis were 
purchased from Aldrich (Milwaukee, WI) or Sigma (St. Louis, MO) if not specified 
otherwise.  Acrylic acid and N,N-dimethylacrylamide were distilled under reduced 
pressure.  N-tert-Butylacrylamide was recrystallized from acetone. 
2.3.2 Synthesis of Polymeric Precursors   
The polymer precursors P1-P3 (Table 2.1) were synthesized (18) by free radical 
copolymerization of DMAA, AA, BuAA, and MA-GG-ONp in acetone at 50 C for 24 h 
using 2,2’-azobisisobutyronitrile (AIBN) as the initiator.  The stoichiometry of the 
comonomers in the feed was manipulated to prepare three copolymer compositions. 
Typically: DMAA (0.8723 g, 8.8 mmol, 44 mol%), AA (0.5765 g, 8.0 mmol, 40 mol%), 
BuAA (0.2544 g, 2.0 mmol, 10 mol%), MA-GG-ONp (0.3856 g, 1.2 mmol, 6 mol%), and 
AIBN (0.1 g, 0.61 mmol) were dissolved in acetone (20 ml), placed in an ampoule, 
purged with N2 for 5 min, and sealed.  After polymerization, the ampoule was cooled, 
opened, the precipitated copolymer filtered off, and washed with an excess of acetone.  
The copolymer was dissolved in MeOH and reprecipitated into diethyl ether/acetone (1/1 


































P1 40 10 47 3 1.68x10-4 3.18x104 4.37x104 
P2 40 10 46 4 2.48x10-4 2.78x104 3.80x104 











2.3.3. Synthesis of Aromatic Azo Bond-Containing Hydrogels (Network A) 
Hydrogels (A1-A3; Table 2.2) were prepared by crosslinking of polymer 
precursors (P1-P3; Table 2.1) with NH2-R-AZO-R-NH2  as described previously 
(Scheme 2.1) (18).  Briefly, NH2-R-AZO-R-NH2 (5.53 mg, 0.0127 mmol) was dissolved 
in DMSO (0.6 ml) to which trifluoroacetic acid (TFA) solution (mol ratio [TFA]: [NH2] 
= 2 in DMSO, 50 μl) was added and mixed at room temperature (Solution A). In this 
solution (Solution A), a polymeric precursor (150 mg, 0.0253 mmol) was dissolved. The 
ratio of [ONp] in the polymeric precursor to [NH2] in the crosslinking agent was 1:1. The 
final volume of the solution was increased to 1 ml with DMSO (final concentration of 
polymer precursor was 15 wt %). The crosslinking reaction was started by the addition of 
a methyl morpholine (MM) solution (mol ratio [MM]: [NH2] = 4 in DMSO, 50 μl), and 
the mixture was thoroughly mixed with a vortex for 30 s.  The resulting solution was then 
quickly transferred to a polymerization mold. The gel point was typically reached after 
about 1 h.  Twenty-four hours later, the gel was retrieved and punched into disks (d = 0.7 
cm; h = 0.17 cm). The disks were immersed in EtOH for 1 week to remove the unreacted 
compounds.  The solvent was gradually changed to a 0.01 N HCl solution and stored 
until used.     
2.3.4. Synthesis of Hydrolyzable Hydrogels (Network B)  
The hydrolyzable hydrogels (H1-H3) were synthesized by free radical 
copolymerization of HPMA with DMHA at 50 C for 24 h using AIBN as the initiator as 
previously described (Scheme 2.2) [18]. Typically, the monomers HPMA (300 mg, 2.095 













Moles of ONp 
(mol) 
Diamine (mg) Diamine (mol) 
A1 150 2.53x10-5 5.53 1.27x10-5 
A2 150 3.72x10-5 8.16 1.86x10-5 






























































































































initiator were dissolved in DMSO to yield a 30 wt % solution.  The solution was 
transferred into a mold, purged with N2 for 5 min, and sealed. The temperature of the 
mold was then increased to 50 0C to start the polymerization.  After 24 h, the gels were 
retrieved and washed with EtOH and stored in 0.01 N HCl solutions (to prevent 
hydrolysis). 
2.3.5. Synthesis of IPN Hydrogels (Network A and Network B) 
The IPN hydrogels (IPN1-4) were prepared by a sequential (two-step) process 
(Scheme 2.3). Briefly, a DMSO solution (0.6 ml) containing HPMA (300 mg, 2.1 mmol), 
DMHA (11.3 mg, 0.067 mmol), AIBN (11 mg, 0.067 mmol), and NH2-R-AZO-R-NH2 
(5.5 mg, 0.0126 mmol) was prepared and thoroughly mixed at room temperature to 
obtain a transparent solution. To this, TFA (0.0504 mmol, mol ratio [TFA]: [NH2] = 2) 
solution (3.88 μl TFA in DMSO, 50 μl) was added and vortexed. Finally, the polymeric 
precursor (150 mg, [ONp] = 0.0252 mmol) was also added and dissolved. The ratio of 
[ONp] in the polymeric precursor to [NH2] in the crosslinking agent was 1:1. A final 
volume of 1 ml was obtained with the addition of DMSO, and then followed by the 
addition of MM (0.10 mmol, mol ratio [MM]: [TFA] = 2, 11.08 μl MM in DMSO, 50 μl). 
The solution was then thoroughly mixed (vortexed ~ 30 s), transferred to a mold, purged 
with N2 for 5 min, and sealed. During this (first) step, the mold was left unperturbed on 
the lab bench for the formation of the first network (Network A). The second step of the 
reaction involved transferring the mold to an oil bath at 50 0C. The mold was left at 50 0C 


































from the mold, cut in disks (d=0.7 cm), and washed using the same method previously 
described. 
2.3.6. Swelling Kinetics  
Swelling studies were performed at pH 7.4 (0.1 M phosphate buffer) at 37 0C. The 
ionic strength was adjusted with NaCl to 0.16.  The swelling of the hydrogels (Network 
A, Network B, and IPN hydrogel) was measured as a function of time after an abrupt 
change in pH from 2 to 7.4 (to mimic the change in pH from the stomach to the small 
intestine).  All measurements were done in triplicate.  The swelling was expressed as a 
swelling ratio Q , where Qt and Q0 are the corresponding wet and dry weights of the gels, 
respectively. 
(1) 
The dry weights of the hydrogels were measured to determine the amount of the 
soluble polymer fraction produced by hydrolysis (for the Network B and IPN hydrogels).  
Following hydrogel synthesis, the gels were washed for 1 week in EtOH and 1 % acetic 
acid (hydrolyzable bonds stable in this condition) and then subsequently dried to 
determine amount of soluble polymer fraction present for each time point.  The swollen 
gels were also characterized by their value of 2 (volume fraction of the polymer in an 









where m1 and d1 are weight and density of the dry polymer, respectively (Network A = 
1.22 g/cm3, Network B (16,21) = 1.19 g/cm3, IPN Network (average) = 1.205 g/cm3), and 
m2 and d2 are the weight and density (1 g/cm3) of solvent, respectively. 
2.3.7 Characterization of the Mechanical Properties of the Hydrogels 
  The modulus of elasticity of the hydrogels was determined as a function of the 
uniaxial compression using a bench comparator (B. C. Ames Co. Waltham, MA) as 
described previously (22).  The swelling and mechanical properties measurements were 
done in conjunction.  Briefly, all gels were immersed in PBS buffer (0.1 M, pH 7.4) at 37 
0C; the mechanical properties were measured by recording the equilibrium height of a 
given gel after applying a force.  After measuring the deformation, the gels were allowed 
to relax to their original height before applying (increased) force again.  The compression 
ratio  (=l/l0 where l and l0 are compressed and initial heights, respectively) was 
measured for a known force F (N).  For each particular time, 8 values of  were 
determined by changing the F.  The modulus of elasticity, G0 (Pa), was calculated using 
the following equation (23).  
(3) 
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2.3.8. Structural Characterization of Hydrogel Networks 
Network A was prepared by the reaction of reactive p-nitrophenyl ester groups 
(group X), located at side chain termini of the polymer precursor, with amino groups of 
the diamine (group Y) (24).  Since the conversion of amine groups (Y) into amide bonds 
(γ) is known, one can calculate the concentration of elastically active network chains 
(EANCs).  There are several factors which will be assumed for the characterization of the 
network structure, like all functional groups having the same reactivity which is 
independent of conversion and also, intramolecular reactions are not considered. In 
characterizing the network, two cases will be considered: one corresponding to 
“relatively long” and commensurable (a) and the other one to “relatively short” (b) bridge 
connecting prepolymer chains (Scheme 2.4).  “Relative” means the length (in equivalent 
units) of the bridge relative to the length of sequence between branch points (ONp 
monomer units) of the polymer precursor chain.  
The crosslinking density was characterized as the concentration of elastically 
active network chains (EANCs), e.  This quantity can be obtained from the experimental 
modulus of elasticity using the branching theory.  The branching theory used here is a 
statistical theory (Theory of Branching Processes) (25, 26).  In the version used here, 
formation of elastically inactive loops is not considered and the values of e are 
considered ideal. The basic distribution of building units in different reaction states is 













Scheme 2.4. Representation of (a) “relatively long” and (b) “relatively short” fused 
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The elastically active network chains are contributed only by component X because 
component Y is bifunctional and does not contain any branch point.  The pgf TX(z) 
expresses the distribution of X units with respect to the number of bonds with infinite 
continuation 
 
The number of EANCs per component unit now depends on our choice (situations a or b) 
(Scheme 2.5).  
In this situation (a), each inner elastically active branch point (having 2 paths to 
infinity) contributes by 3/2 to the number of EANCs, Ne, 
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e 2.5. Illustration of elastically active branch p
 




the concentration of EANCs is given by the equation 
 
where  is specific gravity of the dry polymer. 
For the relatively short bridge, never counted as an EANC, each inner elastically 
branch point contributes by 2(1/2) to the number of EANCs. Each of the two outer 
branch points can contribute by ½ to Ne, if and only if they are coupled with an inner 
elastically active branch point of the adjoining chain (Scheme 2.6).  
The number of outer branch points is equal to the sum of 2ti terms and the 




and the concentration of EANCs is equal to 
 
In replacing the summations by values of the function TX(z) and its derivatives, one 
should recollect that   
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Scheme 2.6. Representation of fused branch points (case (b)). Branches with continuation 




















The values of TX(z) are as follows 
 
2.4. Results and Discussion 
2.4.1. Structure and Properties of IPN Hydrogels  
The properties of the novel IPN hydrogels were compared with the properties of 
individual networks. Using a crosslinking reaction of polymeric precursors, the synthesis 
of azo bond-containing pH-sensitive hydrogels (Network A) was synthesized based on 
previous work (18, 27).  The hydrolyzable network (Network B), which contained 
polyHPMA as the backbone and DMHA as the crosslinking agent, was synthesized by 
free radical polymerization (16).  The crosslinking agent of this network is stable under 
acidic conditions but undergoes Lossen rearrangement at neutral or mildly basic pH (17).  
We combined these two networks to form the IPN structure. Network formation 
conditions (amounts of crosslinker and wt % of monomers) of the hydrolyzable network 
were chosen from our preliminary work to ensure high conversion.  The conversion of 
functional groups for the azo-containing network was approximately 85 % as determined 
  ' '
X X 0 X 1 X0 1
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by measuring the soluble fraction after washing.  The incomplete conversion of the azo- 
containing network is due the formation of network defects in the three-dimensional 
structure due to the presence of elastically inactive cycles (EIC) described previously 
(24).  
2.4.2. Synthesis and Characterization of pH- Sensitive Network A 
Hydrogels composed of azo crosslinks and pH- sensitive monomer units were 
synthesized by crosslinking of polymer precursors (18).  Three different hydrogel 
networks with varying crosslinking density were synthesized (Table 2.3).  The weight 
percent of all precursors and monomers in solution was approximately 15 %.  The 
swelling (Fig. 2.1) and mechanical (Fig. 2.2) properties of these gels were determined.  A 
rapid increase in the degree of swelling was observed upon change of the pH of the 
solution from an acidic to a basic environment.  This rapid increase in swelling is a 
consequence of the ionization of the COOH groups, resulting mainly from the Donnan 
effect.  Apparently, equilibrium was reached within a few hours of pH change (Fig. 2.1).  
Concomitantly with the swelling changes, a decrease in the modulus of elasticity 
occurred (Fig. 2.2), but it remained constant after equilibrium was reached.  
The dependence of the concentration of the elastically active network chains 
(EANCs) was calculated using eqs. (11) and (13) (Fig. 2.3).  The conversion of amine 
groups was measured; hence, the effective crosslink concentration (concentration of 
EANCs) for the given conversion can be calculated.  Table 2.4 shows the composition of 
networks A and concentration of EANCs calculated from gel composition and conversion 
of amine groups (calc. e) and experimental conversion, calculated from equilibrium 































A1 6.5 0.014 1.6310-4 1.9610-4 2.9410-4 1.5010-4 1.9310-4 
A2 9.4 0.021 2.3510-4 2.8310-4 4.2510-4 2.3510-4 3.2010-4 
A3 16.8 0.037 4.2010-4 5.0410-4 7.5610-4 4.2510-4 5.8010-4 



















   cond. all cond all cond all  
A1 0.975 1.4510-4 0.965 0.89 0.010 0.085 1.0 8.7 0.45 
A2 0.982 1.4910-4 0.790 0.738 0.192 0.244 19.5 24.8 0.51 
A3 0.979 2.4010-4 0.755 0.665 0.224 0.344 22.9 35.1 0.54 
xX is the molar fraction of branching units in the copolymer. Ideal e was calculated for 
an ideal system without any network defect; calculated e was obtained by application of 
branching theory for the experimental conversion of the amine groups, Y taking into 
account molecular weight of primary chains and functionality distribution; experimental 
conversion was calculated from the equilibrium modulus in compression. The values of 
intermolecular conversions were calculated from the equilibrium modulus using front 
factor A = 1 (“experimental e”); the intramolecular conversion is equal to the difference 






























Figure 2.1.  Swelling ratio Q (Qt/Q0) of aromatic azo bond-containing hydrogels 
(Network A) as a function of time after an abrupt change in pH (2.0 to 7.4). A1 (-●-); A2 
(--); A3 (-■-).  Hydrogels equilibrated in an acidic solution (pH 2, 0.01 N HCl) were 
transferred to a vial containing 20 ml of PBS buffer solution (0.1 M, pH 7.4).  At selected 
time intervals, the hydrogels were retrieved and weighed to determine the wet weight.  
Then, the hydrogels were washed with EtOH containing 1 % acetic acid for one week, 
dried in vacuo, and their dry weights were determined.  For composition of hydrogels, 



























Figure 2.2. The modulus of elasticity in compression (G) of aromatic azo bond-
containing hydrogels (Network A) as a function of time after an abrupt change in pH (2.0 













Figure 2.3. Dependence of the concentration of EANCs on conversion of amine groups 
(Y) for aromatic azo bond-containing hydrogels A1 (1), A2 (2), A3 (3) for long bridges 









conversion and finite length of primary chains are taken into account, the differences in 
Number-average degree of polymerization of primary chains PX =450, volume fraction of 
polymer during network formation 0 = 0.125 between “calc. e”, and “exptl. e” are 
attributed to formation of elastically inactive cycles. Subsequent to the inspecting of Fig. 
2.3 and Table 2.3, one could conclude that there is no apparent answer to the question of 
which theoretical model is better considering all branch points or fused branch points 
(relatively short bridge).  The difference in concentration of EANCs amounts 
approximately to 30%.  Since the “fused branch points” model offers for the weakest gel 
A1 practically no elastically inactive cycles, we think that the “all branch points” model 
is closer to reality.  Generally, the results seem reasonable; the crosslinking efficiency 
varies between 90 and 65% or 99 - 76% (“fused branch points” model) which is for the 
step addition type of reaction but relatively high dilution a reasonable range.  Also, the 
crosslinking efficiency decreasing with increase of crosslink density is to be expected. 
2.4.3. Synthesis and Characterization of Hydrolyzable Network B 
Three hydrolyzable networks with varying crosslinking density were synthesized 
(Table 2.4) by free radical crosslinking copolymerization.  As expected, the wt% of 
monomers (dilution) during network formation played a critical role in the final 
conversion (28).  A monomeric concentration of 30 wt% was needed to achieve close to 
complete conversion (as determined by measurement of the dry weight).  Apparently, at 
lower monomer conversions, a large amount of the crosslinking agent incorporated into 
the network via one double bond only, or incorporated as elastically ineffective cycles 












Table 2.4. Composition of hydrolyzable hydrogels (Network B) 
 HPMA 
(mol) 








H1 2.095X10-3 97 6.69X10-5 3 2.23X10-3 
H2 2.095X10-3 96 9.01X10-5 4 2.25X10-3 

































Figure 2.4. Changes of swelling ratio Q (Qt/Q0) of hydrolyzable hydrogels (Network B) 
as a function of time after an abrupt change in pH (2.0 to 7.4). H1 (-●-); H2 (--); H3 (-
■-).  Hydrogels were pre-incubated in an acidic solution (pH 2, 0.01 N HCl), then 
transferred to a vial containing 20 ml of PBS buffer solution (0.1 M, pH 7.4). The 
hydrogels were retrieved at selected time intervals, weighed, washed with EtOH 
containing 1 % acetic acid for one week, dried in vacuo, and their dry weights measured. 








degradation rate of the hydrogels as expected.  The higher the crosslinking density, the 
slower the degradation rate and the lower the degree of swelling of the hydrogels (Fig. 
2.4).  It is important to note that as a result of the degradation process and corresponding 
swelling changes, the hydrogels were not at an equilibrium state at the time points 
evaluated.  The decrease of the crosslinking density of the hydrogels with time resulted in 
a decrease of their moduli of elasticity (Fig. 2.5). 
The divinyl monomer (DMHA) contains a hydrolyzable bond in its structure.  
Network B gels are less characterized than Network A gels in that the fraction of pendant  
double bonds is not known.  Therefore, a comparison will be made between the ideal 
concentration of EANCs (all double bonds have reacted and all branch points contribute  
to the number of EANCs) and the “experimental” value of concentration of EANCs 
calculated from the equilibrium modulus.  The crosslinking efficiency is given by the 
ratio of “experimental” to ideal concentration of EANCs.  The results are summarized in 
Table 2.5. 
It is clearly seen that the crosslinking efficiency is much lower than for the 
Network A despite the lower dilution of the polymerizing system B characterized by 
volume fraction of polymer during network formation 0.  The difference in network 
formation mechanism is the main reason for this difference.  It is well known (29, 30) 
that cyclization is very strong during the network formation mechanism with fast 
propagation and increases with increasing fraction of the polyunsaturated monomer. 
2.4.4 Degradation of Hydrolyzable Network B  
Network A does not contain hydrolyzable bonds, but the hydrogels are pH 

























Figure 2.5. The modulus of elasticity (G) in compression of hydrolyzable hydrogels 
(Network B) as a function of the time of the network after an abrupt change in pH (2.0 to 















Table 2.5. Composition and properties of Network type B 
  























H1 0.190 2.0810-4 1.9610-4 2.9410-4 68.6 1.1910-4 60 
H2 0.220 2.7810-4 2.8310-4 4.2510-4 79.1 1.2810-4 70 
H3 0.260 3.4710-4 5.0410-4 7.5610-4 82.6 1.2810-4 83 
 
Number-average degree of polymerization of primary chains PX =420, volume fraction of 















Table 2.6. Increase of the equilibrium degree of swelling and decrease of equilibrium 
modulus of hydrolyzable gels upon cleavage of the hydrolyzable bond 
 
 2 Gsw kPa experimental e mol/cm3 
Time (h) H1 H2 H3 H1 H2 H3 H1 H2 H3 
1.0 0.197 0.228 0.260 68.6 79.1 82.6 11.410-5 12.510-5 12.510-5
5.0 0.170 0.206 0.230 51.1 66.1 58.2 8.9810-5 10.810-5 9.1710-5
21.0 0.101 0.131 0.148 12.3 26.2 37.5 5.4310-5 4.9810-5 6.8510-5
33.0 0.073 0.099 0.122 6.47 9.91 21.6 1.5010-5 2.0710-5 4.2010-5












with time.  Also, the equilibrium modulus exhibits only random fluctuations.  On the 
contrary, hydrolyzable Network B undergoes degradation and the concentration of 
EANCs decreases with increasing time of hydrolysis.  The degree of swelling increases 
as a result of decrease of its crosslink density as well as appearance of hydrophilic 
groups. Thus, this degree of swelling increases and the modulus decreases (Table 2.6).   
2.4.5. Characterization of IPN Hydrogels (Networks A+B) 
The degradability of hydrogels depends strongly on the equilibrium degree of 
swelling (15).  Hydrogels previously designed for colon-specific delivery possess a high  
degree of swelling at neutral pH due to the presence of ionizable monomer units in their 
structure (7,8,14,18,27).  To control the rate of swelling of such hydrogels and achieve a 
more gradual swelling profile, we introduced a second hydrolyzable network.  To this 
end, we synthesized four different IPN hydrogels, combining Network A and Network B.  
The first two gels (IPN1 and IPN2) were synthesized by manipulating the composition of 
Network B, whereas in hydrogels IPN3 and IPN4, the composition of Network A was 
changed (Table 2.7).  The IPN hydrogels were characterized by determination of the time  
dependence of swelling, mechanical properties measurements, and the content of the 
soluble fraction (data not shown).  A close to linear increase of the degree of swelling 
with time was observed for IPN structures after abrupt change of pH from 2 to 7.4, in 
contrast to the corresponding Network A (compare Figs. 2.1 and 2.6).  Controlled time- 
dependent swelling can be achieved with these gels and the burst effect can be 
significantly reduced.  The increase in the degree of swelling is not accompanied by a 

































































Fig. 2.6. Changes of swelling ratio Q (Qt/Q0) of IPN hydrogels as a function of time after 
an abrupt change in pH (2.0 to 7.4). IPN1 (-●-); IPN2 (--); IPN3 (-■-), IPN4 (-◊-).  The 
hydrogels were pre-incubated in an acidic solution (pH 2, 0.01 N HCl) and transferred to 
a vial containing 20 ml of PBS buffer solution (0.1 M, pH 7.4). The hydrogels were 
retrieved at selected time intervals, weighed, washed with EtOH containing 1 % acetic 
acid for one week, dried in vacuo, and their dry weights were measured. For composition 




























Figure 2.7. The modulus of elasticity (G) in compression of IPN hydrogels as a function 
of time after an abrupt change in pH (2.0 to 7.4). IPN1 (-●-); IPN2 (--); IPN3 (-■-), 









homogeneous, showing no evidence of phase separation and network formation of 
Network A and Network B occurs at the same volume.  This means that for both 
networks, the volume fraction at network formation effective in rubber elasticity is the 
same (the EANCs dimensions shrink by the same factor when solvent is removed).  This 
is, however, not so when effect of dilution on network formation (cyclization) is 
considered.  Then, the solvent as well as the other polymer are operative as diluents 
( ).  As in the case of Network B, the experimental concentration of EANC’s relative 
to ideal crosslinking density will be taken as measure of crosslinking efficiency, or 
wastage of crosslinking sites.  The results are shown in Table 2.8. 
The crosslinking efficiency for the IPNs is remarkably low.  Higher dilution 
manifested by lower values of  compared to 0 for individual networks (Tables 2.5 
and 2.6) and thus higher cyclization may be the main reason.  However, it is not excluded 
that the residues of active groups of components of Network A (amine, ONp) affect the 
free radical polymerization by promoting chain transfer and thus a lower degree of 
polymerization of primary chains. 
2.5. Conclusions 
Novel IPN hydrogels were synthesized by a sequential process.  They are 
composed of a pH-sensitive, aromatic azo group- containing network as one component 
(Network A), and a hydrolyzable network as the other component (Network B). 
Network A was produced by crosslinking of a copolymer of N,N-









Table 2.8 Composition and properties of IPN networks 
   ideal (e)A 
mol/cm3 
all branch p. 
ideal (e)B 
mol/cm3 
all branch p. 
ideal (e)IPN 
mol/cm3 
all branch p. 
IPN1 0.132 0.259 4.2410-4 5.1610-4 4.8510-4 
IPN2 0.132 0.266 4.2410-4 8.8010-4 7.1410-4 
IPN3 0.128 0.259 2.9410-4 5.1610-4 4.4310-4 
IPN4 0.138 0.259 6.3010-4 5.1610-4 5.9910-4 
Table 2.8, continued 




% groups  
wasted 
IPN1 0.229 0.391 38.2 0.47110-4 90 
IPN2 0.266 0.398 67.9 0.78810-4 89 
IPN3 0.222 0.388 47.2 0.59110-4 87 
IPN4 0.275 0.398 72.8 0.83510-4 86 
is volume fraction of polymer at network formation operative in rubber elasticity 
theories, ( )A and ( )B are volume fractions of polymer of component A and B, 
respectively, at network formation operative in network formation (the solvent and the 
other component are effective as diluents); ideal (e)A and ideal (e)B are contributions by 
gel A and B, respectively, to the ideal concentration of EANCs of the IPN and (e)IPN is 











glycylglycine p-nitrophenyl ester (polymer precursor) with an aromatic azo group- 
containing diamine ((N,N’-ε-aminocaproyl)-4,4’-diaminoazobenzene). Network B was 
formed by radical crosslinking copolymerization of N-(2-hydroxypropyl)methacrylamide 
with N,O-dimethacryloylhydroxylamine. 
The crosslinking efficiency of radically polymerized Network B is much worse 
than that of step polyaddition Network A.  For Network B, the efficiency goes down to 
10-30%.  The network formation mechanism assisted by dilution during polymerization 
is the main reason. 
In the IPN gels, the crosslinking efficiency is even lower and approaches 10%. In 
addition to higher dilution, possible negative effect of other components on the free-
radical polymerization is likely. Chain splitting and formation of ionizable groups during 
hydrolysis of the gel B is well documented by combined swelling and modulus 
measurements. 
For IPN gels, it seems that formation of hydrophilic ionized groups is not 
accompanied by any major splitting of Network A chains. The dependence of swelling on 
pH and time indicate that the novel IPNs possess the ability to control the burst effect and 
have a potential to protect proteins from enzymatic degradation. It appears that they are 
suitable carriers for oral protein/peptide delivery. 
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such as peptides (4, 5, 8, 12-14), antibodies (15, 16), antibody fragments (17, 18), 
carbohydrates (19), and lectins (20).  The ensuing change in their internalization 
mechanism from endocytosis to receptor-mediated endocytosis results in enhanced 
uptake of targeted conjugates.   
 Combinatorial peptide library techniques accelerated the identification of 
targeting peptides (21-24) and stimulated their use due to their ease of synthesis, low 
immunogenicity, and desirable pharmacokinetic properties.  Recently, there has been 
considerable effort to develop peptides or proteins that can target colon cancers (25-28).  
Kelly et al. (29) used bacteriophage-derived libraries to select peptides binding to colon 
cancer cells.  They used a subtraction method to distinguish between well-differentiated 
HCT116 and poorly differentiated HT29 colon carcinoma cells.  Utilizing this method 
yielded peptides that displayed a consensus RPM motif, which mediated preferential 
binding to HT29 cells.  A particular nonapeptide, CPIEDRPMC, was derived from a 
disulfide constrained CX7C library and shown to bind specifically to poorly differentiated 
colon carcinoma cells (HT-29) (29). 
 Restraining the peptide backbone into a more defined conformation through 
cyclization is activity perused in synthetic peptide design (30).  Conformational 
constrains may increase the probability of optimal peptide-receptor recognition, thereby 
increasing its binding affinities (31).  However, disulfides can be reduced 
physiologically; hence, our strategy was to cyclize the peptide via an amide linkage (32-
34).  Specifically, a peptide (RPM) was designed that is cyclized via a side chain of 
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synthesized as described previously.  Solvents and reagents were of analytical grade and 
were used without further purification.  They were purchased from Aldrich (Milwaukee, 
WI) or Sigma (St. Louis, MO) if not specified otherwise.  2-Chlorotrityl chloride resin, 
all Nα-Fmoc protected amino acids, PyBOP, and HOBt were purchased from 
Novabiochem (San Diego, CA); DMSO (99.9%) was purchased from EMD Chemicals 
(Gibbbstown, NJ); TFA, DMF, methanol, and piperidine were purchased from VWR and 
AIBN was from Soltech Ventures (Beverly, MA).   
3.3.2. Peptide Synthesis  
 Peptides were synthesized using a solid-phase methodology and a manual 
Fmoc/tBu strategy on 2-chlorotrityl resin as described previously.  Briefly, the peptides 
were prepared from the C-terminal by consecutive addition of protected amino acids (2.5 
equiv.), PyBop (3 equiv.), and diisopropylethylamine (2.5 equiv.) to the first amino acid 
Fmoc-Glu(ODmab)-OH which was bound to 2-chlorotrityl resin.  After the synthesis of 
the linear sequence, the peptide was cyclized. The cyclization (amide-bond formation) of 
the peptides was carried out via side-chain lysine and glutamic acid.  These two amino 
acids were protected via a quasi-orthogonally-protected side-chain; namely, glutamic acid 
side-chain was protected via α-4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-
methylbutyl]amino}benzyl ester (ODmab)) and a lysine amino acid via N-ε-1-(4,4-
dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde); both these groups can be 
selectively removed with 2% v/v hydrazine in DMF solution. The cyclization step was 
carried out with PyBop (3 equiv.) in DMF for 24 h.  After the desired peptide sequences 
were synthesized, the resulting dry resin-bound peptides were cleaved and side-chain 
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polymer concentration was 10 wt %).  After the reaction, the volume of the reaction 
mixture was reduced in vacuo and the conjugate isolated by precipitation into an excess 
of acetone.  The content of RPM1 in the polymeric conjugate was measured by UV-
spectrophotometry (280 nm, ε = 6990 M-1 cm-1, in PBS buffer (47)).  This polymeric 
conjugate was fractionated into a low (P(L)-RPM1-FITC) and high (P(H)-RPM1-FITC) 
molecular weight portion and the content of RPM was 1 (30 Kd polymer) and 3.2 (100 
Kd polymer) peptides per chain, respectively. 
3.3.4 Synthesis of HPMA Copolymer – RPM2 Conjugate 
 HPMA copolymer-RPM2 conjugate, P-RPM2-FITC (Fig. 3.2), was synthesized 
by free radical copolymerization of HPMA, macromonomer RPM2, and MA-FITC.  
Typically: HPMA (40 mg, 0.28 mmol, 91 mol%), MA-FITC (3.26 mg, 0.0061 mmol, 2 
mol%), macromonomer RPM2 (44.33 mg, 0.021 mmol, 7 mol%), and AIBN (0.75 mg, 
0.0046 mmol) were dissolved in methanol (0.5 mL), placed in an ampoule, purged with 
N2 for 5 min, and sealed.  The polymerization proceeded at 50 oC for 24 h.  Then, the 
ampule was cooled, opened, and the copolymer isolated by precipitation into an excess of 
diethyl ether/acetone (1/1 v/v).  The yield of copolymer was 62 mg (~70 %).  The content 
of peptide in the polymeric conjugate was measured by a UV-spectrophotometry (280 
nm, ε = 6990 M-1 cm-1, in PBS buffer (47)). This polymeric conjugate was also 
fractionated into a low (P(L)-RPM2-FITC) and high (P(H)-RPM2-FITC) molecular 
weight portion and the content of RPM was 3.5 (41 Kd) and 17 (228 Kd) peptides per 




3.3.5 Synthesis of Control Copolymer 
 FITC-labeled HPMA copolymer (without peptide), P-FITC (Fig. 3.2), was 
obtained by aminolysis of the side-chains of the polymer precursor P-FITC-TT.  
Typically: P-FITC-TT (200 mg) was dissolved in methanol (2 mL); to this solution, 
excess 1-aminopropan-2-ol was added and the reaction mixture stirred at r.t for 30 min.  
The hydrolyzed polymer reaction mixture was then run on a Sephadex™ LH-20 to 
separate the polymer and low molecular weight compounds.  The copolymer fractions 
were concentrated under reduced pressure and precipitated into an excess of acetone.  
3.3.6 Fractionation of Copolymers   
 To obtain narrow molecular weight fractions, polymer conjugates, P-RPM1-
FITC, P-RPM2-FITC, and the control polymer, P-FITC, were applied on a preparative 
size exclusion Superose 6 (HR16/60) column.  Fractions were collected using an 
automated fraction collector.  Fractions from several runs were subsequently pooled into 
4 separate collections.  These were then dialyzed extensively against DI water and freeze-
dried.  The first and last ladder (corresponding to high and low molecular weight) was 
used for further experiments.  
 The molecular weight and molecular weight distribution of copolymers were 
measured on the ÄKTA FPLC system (GE Healthcare, formerly Amersham) equipped 
with UV and RI detectors using a Superose 6 HR10/30 column with PBS (pH 7.3) and 
PBS/acetonitrile (70/30) as the mobile phase.  The average molecular weights were 
calculated using a calibration with polyHPMA fractions. The characterization of all 







Table 3.1. Characterization of HPMA copolymer-peptide conjugates 
Conjugates Mw 
(kDa) 
Pa Peptide / 
macromolecule 
Kdb
M x 10-6 
P(H)-RPM1-
FITC 
100.5 1.25 3.2 912 
P(L)-RPM1-
FITC 
30.5 1.14 1 601 
P(H)-RPM2-
FITC 
228 1.1 17 575 
P(L)-RPM2-
FITC 
41 1.2 3.5 416 
P(H)-FITC 
(Control) 
100.5 1.25 ---- ---- 
P(L)-
FITC(Control) 
32.8 1.22 ---- ---- 
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3.3.9 Flow Cytometry 
For flow cytometry, cells were grown on 12-well plates (seeded 24 h before 
incubation, 1 × 105 cells/well) and then uptake studies were conducted by incubating with 
polymeric conjugates or free peptide for selected time intervals.  The cells were then 
washed three times with warm DPBS.  The cells were then detached with trypsin-EDTA 
solution.  Collected cells were incubated for 15 min with warm PBS/2% BSA.  A 
FACScan (Becton Dickinson Biosciences, Mountain View, CA) equipped with a single 
488 nm argon laser was used.  After the flow cytometer was set for green (FL-1) and red 
(FL-2) fluorescence, the data were collected and analyzed with Cell Quest software (BD 
Biosciences) after appropriate gating. 
3.3.10 Radiolabeling and Binding Experiments 
 The polymeric conjugates and free RPM peptide were labeled with 125I using the 
Iodogen method.  The conjugates or peptide (300 µl of a solution having a concentration 
equivalent to 1.0 mg/ml in PBS, pH 7.4), and 10 µl (0.5 mCi) of Na125I were mixed in an 
Iodogen tube.  The reaction was left for 15 min while being periodically mixed.  The 
unbound iodide was separated from the labeled conjugate by passing the reaction mixture 
over a Sephadex G-25 column, which had been pre-equilibrated with PBS and BSA.  The 
labeled peptide or conjugates (specific activity 45-65 µCi/mg) were stored at 4 0C.  
 The antigen binding affinity constants (Kd) of the free and polymer-bound 
peptides were determined by radio-assay.  Cells were plated in 96-well plates and grown 
for 24 h until 80-90 % confluence.  One hour before the experiment, cells were switched 
from growth medium to DPBS, pH 7.4, and kept at 4 0C.  Binding experiments were 
initiated by adding PBS solutions containing labeled free peptide or conjugates at various 
99 
 
concentrations (also chilled at 4 0C).  Cells were incubated with the ligands for 1 h and 
then the unbound ligand was removed using an aspirator.  Cells were solubilized with 
200 µL of 1 N NaOH for 30 min and subsequently counted for radioactivity.   
3.4 Results and Discussion 
 In HPMA copolymer - RPM conjugates, RPM was attached to the HPMA 
copolymer backbone via two spacers of different lengths (Fig. 3.2; Table 3.1), 
glycylglycyltyrosyltryptophan (P-RPM1-FITC) and 8-amino-3,6-dioxaoctanoyl-8-amino-
3,6-dioxaoctanoyl-8-amino-3,6-dioxaoctanoyltyrosyltryptophan (P-RPM2-FITC).  The 
peptides used in the preparation of conjugates were synthesized by solid phase peptide 
synthesis.  The amide-bond cyclization between K and E was performed on peptide still 
attached to the beads.  Two techniques were used for conjugate synthesis, namely 
polymeranalogous attachment of RPM1 to a HPMA copolymer precursor containing GG 
side-chains terminated in reactive TT groups (conjugate P-RPM1-FITC) and by 
copolymerization of macromonomer RPM2 with HPMA and MA-FITC.  During the 
polymeranalogous attachment of RPM1 to HPMA copolymer precursor, there is a 
possibility of Arg side-chain reactivity.  However, there was no broadening of the SEC 
profile after the reaction was detected (when compared to the profile before the reaction).  
To avoid this problem, the monomeric form of the peptide (RPM2) was synthesized and 
incorporated into the HPMA copolymer conjugate by copolymerization. 
 The HPMA copolymer conjugates were fractionated on a preparative Superpose 6 
(HR16/60) column.  Two fractions, a high molecular weight sample and a low molecular 
weight sample, were isolated and used in the experiments.  On Fig. 3.3, the molecular 
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RPM1-FITC, were internalized faster than high molecular weight conjugates (Fig. 3.6B), 
P(H)-FITC and P(H)-RPM1-FITC (Fig. 3.6B).   
 One important factor in the biorecognition of polymer conjugates is the 
spacer length between the polymer backbone and the recognition (targeting) moiety (41).  
To test the impact of spacer length on biorecognition, a longer spacer, 8-amino-3,6-
dioxaoctanoyl-8-amino-3,6-dioxaoctanoyl-8-amino-3,6-dioxaoctanoyltyrosyltryptophan, 
was introduced between the HPMA copolymer and RPM moiety (conjugate P-RPM2-
FITC). As mentioned above, the synthesis of P-RPM2-FITC was carried out in a one-step 
process by copolymerization of HPMA, MA-FITC, and macromonomer RPM2.  This  
copolymer was also fractionated and two fractions, namely a high molecular weight (228 
kDa) sample, P(H)-RPM2-FITC, and a low molecular weight (41 kDa) sample, P(L)- 
RPM2-FITC, were prepared (Table 3.1).  Flow cytometry data (Fig. 3.7) revealed that 
introduction of the longer spacer resulted in a clear distinction between RPM containing 
conjugates, P(H)-RPM2-FITC and P(L)-RPM2-FITC, and control polymers, P(H)-FITC 
and P(L)-FITC.  For both, high molecular weight and low molecular weight conjugates,  
the RPM-containing conjugate produced a larger shift of the flow cytometry profile than 
the corresponding control polymer (without RPM).  It is interesting to note that the shift 
of the flow cytometry profile appeared to be larger for the low molecular weight 
conjugate.  The decreased biorecognition of the high molecular weight conjugate might 
be the consequence of the conformation of the macromolecule in solution.  Apparently, 
the RPM peptide is less accessible in the high molecular weight conjugate.  The 
intramolecular interactions of peptide-terminated side chains may lead to the formation of 



































outside.  Formation of unimolecular micelles in HPMA copolymer conjugates was 
observed previously (48).  The results discussed above indicated that the binding constant 
of RPM to HT-29 cells would be modest.  To quantitatively characterize the interaction 
of free and HPMA copolymer-bound RPM, a radioiodination assay, using cell 
monolayers, was employed and dissociation constants determined.  The free peptide 
(RPM3) and HPMA copolymer – RPM conjugates were incubated with chilled cells (4 
0C) for 1 h in PBS buffer.  The dissociation constants (Table 3.1) were calculated using 
SigmaPlot by fitting the binding data to a one-site saturation ligand binding equation.  
The dissociation constants of free and HPMA copolymer-bound peptides were of the 
same order (10-4 M-1).  The results corroborated internalization and flow cytometry data.  
Binding of low molecular weight conjugates was enhanced when compared to high 
molecular weight ones.  The highest binding was observed for the P(L)-RPM2-FITC 
conjugate.  Several factors may contribute to enhanced binding of this conjugate: length 
of spacer, number of RPT moieties per macromolecule, and conformation of the 
macromolecule in solution.  These data evidently showed the need of balancing the 
physical as well as biological components to achieve optimal cellular biorecognition.  
 In summary, these results showed that water-soluble polymers (like HPMA 
copolymers) can be used for facile attachment of targeting moieties and therapeutics.  
Additionally, the RPM peptide possesses a potential as a targeting moiety to deliver 
therapeutics specifically to colon cancer cells.  It was demonstrated that the spacer length 
between the polymer backbone and the RPM peptide plays an important role in 
biorecognition.  Optimizing the physicochemical properties of the copolymers is crucial 
in achieving favorable biorecognition (49).  One pathway to follow is the modification of 
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RPM structure, by systemically altering the nonessential amino acids (50), to improve 
biorecognition.  Currently, the receptor-binding site for this peptide is unknown; further 
experiments are essential to identify the receptor and its density on cellular surface.  This 
would permit us to design conjugates, which could benefit from multivalent binding to 
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IN VIVO EVALUATION OF NOVEL COLON CANCER  
TARGETED HPMA-9-AMINOCAMPTOTHECIN  
CONJUGATES TREATED LOCALLY  
AND SYSTEMICALLY 
4.1. Abstract 
Two novel, linear polymeric systems were designed for systemic delivery, one 
containing a biorecognizable sequence and the other without. This polymeric system was 
compared to a polymer designed for local delivery. The former system P-GFLG-9-AC 
was a carrier composed of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer, 9-
aminocamptothecin (9-AC), and with or without a biorecognizable cyclic nonapeptide. 
The anticancer drug 9-AC was attached via a spacer consisting of a lysosomally 
degradable linker, namely an oligopeptide spacer glycylphenylalanylleucylglycyl 
(GFLG) and a self-eliminating 4-aminobenzyl alcohol structure. In the latter system, a 
copolymer of HPMA and 9-aminocamptothecin bound via an aromatic azo bond (P-
AZO-9AC) and a self-elimination spacer was synthesized. Therapeutic efficiency of a 
systemic versus local approach was evaluated in vivo using a noninvasive 
bioluminescence imaging tumor model. To this end, six groups were compared: a) 
untreated, b) free drug (oral), c) P-AZO-9-AC (oral), d) P-GFLG-9-AC (i.v.), e) P-GFLF-




(oral). Mice treated with the polymer conjugates containing 9-AC or free drug had 
significantly longer tumor growth delay compared to untreated controls. Polymer 
conjugates given parenteral performed slightly better than the conjugates given orally. No 
significant difference in the therapeutic effects among the targeted or untargeted 
conjugates was observed. 
4.2. Introduction 
Colon cancer is the second leading cause of cancer-related death in the United 
States (1). Its death rate has not significantly changed over the past 20 years in spite of 
surgical procedures that have vastly improved in the same period (2). This is likely due to 
the late stage at which CRC is diagnosed, and the intrinsically high, nonspecific toxicity 
from which conventional chemotherapeutic treatments suffer (3, 4). Due to failure and 
limitation of current therapies, the development of novel approaches for the treatment of 
colon cancer is currently under intense investigation (5, 6).  
The mainstay of treatment for metastatic or recurrent colorectal cancer is 
chemotherapy. For many years, 5-fluorouracil (5-FU), has been the main treatment 
option; however, modest efficacy has been observed. Recently, several new 
chemotherapeutic agents, including capecitabine, oxaliplatin, and various derivatives of 
camptothecin have become available. Camptothecin (CPT), discovered in the 1960s (7) 
and later identified as an unequivocal inhibitor of topoisomerase I (8, 9), is a naturally 
occurring alkaloid. During Phase I and Phase II clinical trials, it showed strong antitumor 
activity among patients with gastrointestinal cancers, though it caused severe side effects, 




structure activity relationships of camptothecins, various analogs have been developed 
that increase its solubility and reduce its side effects (10). One analog that demonstrated 
superior topo I inhibitory activity than its parent compound or two other clinically 
approved derivatives (topotecan or irinotecan) was 9-aminocamptothecin (9-AC) (IDEC-
132) (11). However, 9-AC- has a major drawback related to dose limiting toxicity, which 
ultimately resulted in discontinuation of Phase II studies (12, 13).  
The use of hydrophilic polymers as drug delivery vehicles is well accepted and 
they have dramatically changed the way we diagnose and treat patients. Polymeric 
carriers based on N-(2-hydroxypropyl)methacrylamide (HPMA) have been extensively 
studied (14-17).  Drugs incorporated in polymeric carriers have various advantages (when 
compared to low-molecular weight drugs), including long-lasting circulation in the 
bloodstream, decreased nonspecific toxicity of the conjugated drug, increased solubility 
of hydrophobic compounds, and decreased immunogenicity of the targeting moiety (18, 
19).  
Strategies of incorporating 9-aminocamptothecin within polymeric carriers have 
dramatically reduced the nonspecific toxicity of the parent drug (20-22). A wide array of 
orally bioavailable colon-specific delivery systems incorporating 9-AC have been 
designed and synthesized previously (23-27). This approach has utilized the drug bound 
to a copolymer of HPMA via an aromatic azo bond and a self-elimination spacer (28-30). 
After selectively targeting the macromolecule to the colon, the unmodified drug can be 
released at the site of action (31). Using this strategy, Gao et al. (28) have shown a 
dramatic improvement in the pharmacokinetic profile with a substantially higher local 




However, it is prudent to utilize a systemic therapy approach for the treatment of 
metastatic colorectal cancer. Macromolecules afford the advantage of nonspecific 
accumulation inside solid tumors. This phenomenon is due to the so-called Enhanced 
Permeability and Retention (EPR) effect (32). However, the drawback of conventional 
polymeric delivery systems relates to the slow rate of internalization after passive 
targeting to tumor tissue through the endocytic pathway.  Hence, there is an immense 
interest in designing a new generation of molecularly targeted therapeutics through 
tumor-specific mAbs or ligands that bind to receptors that are present on tumor cells. 
Development of these systems can potentially lead to a higher local concentration and 
enhance tumor cytotoxicity as compared to their untargeted counterpart. Furthermore, 
targeted therapeutics may change the mechanism of cell entry from fluid phase 
pinocytosis to receptor-mediated endocytosis. The latter mode of entry results in a faster 
rate of internalization when compared to fluid phase (nontargeted systems) uptake (33) 
and is thus more efficient. Numerous antibodies (34, 35) and peptides (36-40) have been 
developed to target colon cancer. The most interesting targeting agent for colorectal 
cancers is based on peptide sequences. Combinatorial peptide library techniques have 
accelerated the identification of targeting peptides and stimulated their application due to 
their ease of synthesis, low immunogenicity, and desirable pharmacokinetic properties.  
Two of the most promising sequences found in literature are the HEWSYLAPYPWF (39) 
sequence targeted to WiDr cells and the nonapeptide, CPIEDRPMC, derived from a 
disulfide constrained CX7C library and shown to bind specifically to poorly differentiated 
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systemic versus local approach was evaluated in vivo using a noninvasive orthotopic 
tumor model. 
4.3. Materials and Methods 
4.3.1. Chemicals 
9-Aminocamptothecin was a generous gift from the National Cancer Institute. 9-
N-{4-[4-(N-methacryloyl-N′-oxymethylcarbonyl-propyldiamino)-3-chlorophenyl-azo] 
benzylmethoxycarbonyl}aminocamptothecin (29), HPMA (42), and MA-GFLG-OH (43)  
were synthesized as described previously.  Solvents and reagents used for synthesis were 
purchased from Aldrich (Milwaukee, WI) or Sigma (St. Louis, MO) if not specified 
otherwise.  
 4.3.2. Synthesis MA-GFLG-ABA 
MA-GFLG-OH (1 g, 2.17 mmol) was dissolved in 5 ml dichloromethane (DCM), 
to which were added 4-Aminobenzyl alcohol (0.267 g, 2.17mmol) and N,N′-
dicyclohexylcarbodiimide (0.477g, 2.17 mmol). This solution was stirred at r.t overnight. 
The solvent was concentrated under vacuum and dicyclohexylurea (DCU) removed by 
filtration. The product was purified using a preparative HPLC.  The mass for N-
methacryloylglycylphenylalanylleucylglycyl aminobenzyl alcohol (MA-GFLG-ABA) 
was verified via MALDI-TOF MS: (MH+) 565, found 565.76, and TLC showed one spot 
in ethyl acetate:hexane (1:1).   
4.3.3. Synthesis MA-GFLG-ABA-9AC 
9-AC (0.05 mg, 0.14 mmol), dissolved in 15 ml methylene chloride, was mixed 




phosgene and solvent were removed under vacuum. The residue was dissolved in 15 ml 
DCM, MA-GFLG-ABA (0.078 g, 0.14 mmol) and potassium carbonate (0.039 g, 0.28 
mmol) were added, and stirred for 48 h at r.t. After evaporation of the solvent, the MA-
GFLG-ABA-9AC (Fig. 4.1) was purified by preparative HPLC. The mass was verified 
via MALDI-TOF MS: (MH+) 955, found 978.76 (Na+ peak).  The target compound was 
also verified via TLC using ethyl acetate:hexane (1:1) as mobile phase.  
4.3.4. Peptide Synthesis  
Peptides were synthesized using a solid-phase methodology and a manual Fmoc/tBu 
strategy on 2-chlorotrityl resin as described previously (44).  Briefly, the peptides were 
prepared from the C-terminal by consecutive addition of protected amino acids (2.5 
equiv.), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop) 
(3 equiv.), and diisopropylethylamine (2.5 equiv.) to the first amino acid Fmoc-
Glu(ODmab)-OH which was bound to 2-chlorotrityl resin.  After the synthesis of the 
linear sequence N-methacryloylglycylglycine-6-aminohexanoyl-8-amino-3,6-
dioxaoctanoyl-8-amino-3,6-dioxaoctanoyl-8-amino-3,6-dioxaoctanoyl- 
YWKPIEDRPME, the peptide was cyclized (Fig. 4.2). The cyclization (amide-bond 
formation) of the peptides was carried out via side-chains of lysine and glutamic acid. 
These two amino acids were protected via a quasi-orthogonally-protected side-chain, 
namely glutamic acid, that  was protected via α-4-{N-[1-(4,4-dimethyl-2,6- 
dioxocyclohexylidene)-3-methylbutyl]amino}benzyl ester (ODmab)) and lysine via N-ε-
1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde); both these groups 







































































was carried out with PyBop (3 equiv.) in DMF for 24 h.  After the desired peptide 
sequences were synthesized, the resulting dry resin-bound peptides were cleaved and 
side-chain deprotected using a TFA/H2O/ethanedithiol/triisopropylsilane (94.5:2.5:2.5:1) 
cocktail. Crude peptides were purified by RP-HPLC (Agilent, 1100 Series with 
preparative Microsorb MV C18 column, 300 Å 5 µm, 250 × 22 mm, flow rate 8 
mL · min-1) employing a gradient from 2% to 90% B over 100 min, where buffer A was 
0.1% TFA in water and buffer B 0.1% TFA in acetonitrile.  The purity of the peptides 
was verified with analytical RP-HPLC.  Peptide structures were ascertained by mass 
spectra determined by MALDI-TOF (Voyager-DE STR Biospectrometry Workstation, 
PerSeptive Biosystems).   
4.3.5. Synthesis of a HPMA Copolymer GFLG–9AC Conjugate 
HPMA copolymer-9AC conjugate, P-9AC, was synthesized by free radical 
copolymerization of HPMA and MA-GFLG-ABA-9AC.  Typically: HPMA (100 mg, 0.7 
mmol, 98 mol%), MA-GFLG-ABA-9AC (13.6 mg, 0.014 mmol, 2 mol%), and AIBN 
(3.5 mg, 0.021 mmol) were dissolved in methanol (0.5 mL), placed in an ampoule, 
purged with N2 for 5 min, and sealed.  The polymerization proceeded at 50 oC for 24 h.  
Then, the ampoule was cooled, opened, and the copolymer isolated by precipitation into 
an excess of diethyl ether/acetone (1/1 v/v).  The yield of copolymer was 80 mg (~70 %).  
The content of 9-AC in the polymeric conjugate was measured by UV-spectrophotometry 






4.3.6. Synthesis of HPMA Copolymer GFLG–9AC-RPM Conjugate 
HPMA copolymer-9AC conjugate, P-9AC-RPM, was synthesized by free radical 
copolymerization of HPMA, MA-GFLG-ABA-9AC, and RPM macromonomer.  
Typically: HPMA (100 mg, 0.7 mmol, 96 mol%), MA-GFLG-ABA-9AC (13.9 mg, 
0.0145 mmol, 2 mol%), RPM macromonomer (30 mg, 0.0145 mmol, 2 mol%), and 
AIBN (3.6 mg, 0.022 mmol) were dissolved in methanol (0.5 mL), placed in an ampoule, 
purged with N2 for 5 min, and sealed.  The polymerization proceeded at 50 oC for 24 h.  
Then, the ampoule was cooled, opened, and the copolymer isolated by precipitation into 
an excess of diethyl ether/acetone (1/1 v/v).  The yield of copolymer was  100 mg (~70 
%).  The content of drug (9-AC) and peptide in the polymeric conjugate was measured by 
UV-spectrophotometry (9-AC: 360 nm, ε = 12000 M-1 cm-1, in MeOH, peptide:  280 nm, 
ε = 6990 M-1 cm-1, in PBS buffer) (Fig. 4.3C) (Table 4.1).  
4.3.7. Synthesis of HPMA Copolymer AZO-9AC Conjugate 
 HPMA copolymer-9AC conjugate, P-9AC-RPM, was synthesized by free radical 
copolymerization of HPMA and MA-AZO-9AC.  Typically: HPMA (100 mg, 0.7 mmol, 
96 mol%), MA-AZO-9AC (12.09 mg, 0.0145 mmol, 2 mol%), and AIBN (3.6 mg, 0.022 
mmol) were dissolved in methanol (0.5 mL), placed in an ampoule, purged with N2 for 5 
min, and sealed.  The polymerization proceeded at 50 oC for 24 h.  Then, the ampoule 
was cooled, opened, and the copolymer isolated by precipitation into an excess of diethyl 





















Table 4.1. Characterization of HPMA copolymers  
aDetermined by SEC using the AKTA FPLC system (Pharmacia) on Superose 6 columns 
calibrated with PHPMA samples; b polydispersity (Mw/Mn); cDetermined by UV 











Pb Peptide / 
macromolecule
9-AC content 
mol . g-1 
9-AC 
Wt % 
P-GFLF-9AC 34 1.5 --- 1.48x10-4 16.48 
P-GFLG-9AC-
RPM 
30 1.4 2 4.32x10-5 4.30 
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was prepared for sterile surgery. A small abdominal incision was made, and the cecum 
was exteriorized and isolated on sterile gauze. A suspension of luciferase-expressing HT-
29 cells (2 X 106 cell/100 µl/mouse) containing 0.5 mg of “matrigel” basement 
membrane matrix (Matrigel, Becton Dickinson Bioscience, MA) were injected into the 
cecal wall from the serosal side with a 28-gauge needle. After injection, the cecum was 
returned to the abdominal cavity and the incision in the abdominal wall sealed using the 
tissue adhesive. Orthotopic tumors usually developed within 1 week after the 
transplantation. 
4.3.11. In Vivo Imaging  
Five minutes prior to imaging, mice were anaesthetized with ketamine (100 
mg/kg intraperitoneally) and xylazine (10 mg/kg intraperitoneally), and an aqueous 
solution of luciferin (150 mg/kg intraperitoneally) (Xenogen, Alameda, CA). Animals 
were placed into the light-tight chamber of the CCD camera system (IVIS 100, 
Xenogen), and a grayscale body surface reference image (digital photograph) was taken 
under weak illumination. After switching off the light source, photons emitted from 
luciferase expressing cells within the animal body and transmitted through the tissue were 
quantified over a 1 min period using the software program “Living Image” (Xenogen) as 
an overlay on Igor (Wavemetrics, Seattle, WA). For anatomical localization, a 
pseudocolor image representing light intensity (blue, least intense; red, most intense) was 
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synthesized by solid phase peptide synthesis.  The amide-bond cyclization between K and 
E was performed on peptide still attached to the beads. The novel targeted and untargeted 
conjugates were synthesized, by copolymerization of HPMA, MA-GFLG-9AC, and with 
or without macromonomer RPM, respectively.  In the latter system, a copolymer of 
HPMA and 9-aminocamptothecin bound via an aromatic azo bond (P-AZO-9AC) and a 
self-elimination spacer was synthesized. This copolymer was also synthesized by free 
radical polymerization of HPMA and MA-AZO-9AC. 
The HPMA copolymer conjugates were purified on a Sephadex LH20 column to 
remove any unreacted monomers. The molecular weights distributions were characterized 
by using an analytical Superose 6 (HR16/60) column (Table 4.1).  
Design of an animal model of colorectal cancer that can be used to track tumor 
progression noninvasively is very important in the development and evaluation of novel 
therapeutics. The result presented demonstrates the remarkable sensitivity of 
bioluminescence-based imaging strategies and the ability to quantitatively measure tumor 
burden over the entire spectrum of disease. This approach has several advantages over 
conventional tumor models. First, the sensitivity of cell detection in vivo is surprisingly 
high. Only 5 days after tumor injection, a strong signal can be detected, with progressive 
increase in signal intensity with increase in tumor size. Second, since cells can be 
detected deep with the tissue, tumor cell trafficking and metastasis could be visualized. 
Using this technology, it is possible to study early stages of tumor development long 
before any clinical signs of disease are evident as well as the efficiency of therapeutic 




In these initial experiments, the tranduced cell line HT-29-luc was implanted into 
female nu/nu animals as proof of principle. Initial studies showed that therapeutic 
efficiency of the polymer conjugates could be visualized noninvasively. The effect of 9-
AC and 9-AC conjugates, P-AZO-9AC, P-GFLG-9AC, and P-GFLF-9AC-RPM, were 
studied. A drug dose of 2 mg/kg 9-AC equivalent on each of days 1, 5, and 9 was used 
based on previously published results from Conover et al. (47). 
Antitumor effect of HPMA-9AC conjugates was assessed in orthotopic tumor 
model using bioluminescence imaging. A retroviral transduction system was used for the 
delivery of a luciferase gene into HT-29 cells. This yielded a transduced cells line that 
showed positive expression of luciferase (Fig. 4.4). These cells (2x106 cell/mice) were 
then injected into the cecal wall of female nu/nu mice from the serosal side, which 
allowed the noninvasive visualization of tumor progression (Fig. 4.5).  Only 60 % of the 
mice injected with cell-generated tumors. Repetitive imaging of individual mice showed 
that the cell growth followed an exponential growth.  The tumor distribution pattern of 
one representative control animal shows tumor metastatic infiltration (Fig. 4.6).  
Mice that generated tumors were randomly divided into six groups (n=6): a) 
untreated, b) free drug (oral), c) P-AZO-9-AC (oral), d) P-GFLG-9-AC (i.v.), e) P-GFLF-
9-AC-minPEG-PRM (i.v.), f) combination of P-GFLG-9-AC (i.v) and P-AZO-9-AC 
(oral).  As expected, animals within a control group that received no treatment showed a 
continuous increase in their tumor signal (Fig. 4.7A). In contrast, treatment groups (n=6) 
resulted in a substantial reduction in tumor within 20 days. This was followed by a 




































































































































































remaining observation time of 5 weeks (Fig. 4.7B-D). Polymer conjugates given 
systemically performed slightly better than the conjugates given orally (Fig. 4.76D). 
However, there was no difference in the therapeutic effects among the targeted or 
untargeted conjugates (Fig. 4.7C). 
While all delivery systems improved survival of animals with tumors, no cures 
were obtained. This model can be used for future experiments with dose escalation and 
biodistribution studies to obtain more insight into the delivery systems used.  
In conclusion, bioluminescence-based imaging strategies are a powerful tool to 
study tumor progression. This noninvasive, highly sensitive, and quantitative approach is  
ideally suited for evaluation of novel drug delivery systems. Further evaluation using 
both systemic and local approach is warranted to obtain conclusive results regarding the 
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CONCLUSIONS AND FUTURE WORK 
5.1. Specific Aim 1. Design and Synthesis of Novel Interpenetrating  
Network (IPN) Hydrogels for Colon-Specific Drug Delivery 
To investigate the structure - property relationship of interpenetrating network 
(IPN) hydrogels suitable as colon-specific drug delivery systems, we have synthesized 
and evaluated the properties of IPN hydrogels composed from pH-sensitive, aromatic azo 
group-containing hydrogels as the first component, and a hydrolyzable network as the 
second. Interpenetrating network (IPN) hydrogels composed of pH-sensitive, aromatic 
azo group-containing hydrogels as one of its components (Network A), and a 
hydrolyzable network as the other were synthesized (Network B ) and were prepared by a 
sequential process. The properties of IPNs with the aim of identification of structures 
suitable as colon-specific drug delivery systems were investigated.  
The first network was formed by crosslinking of a reactive polymer precursor 
(copolymer of N,N-dimethylacrylamide, acrylic acid, N-tert.butylacrylamide, and N-
methacryloyl-glycylglycine p-nitrophenyl ester) with an aromatic azo group-containing 
diamine ((N,N’-ε-aminocaproyl)-4,4’-diaminoazobenzene).  The second network was 
formed by radical crosslinking copolymerization of N-(2-hydroxypropyl)methacrylamide 




homogeneous and showed no evidence of phase separation. The composition of the 
hydrogels was manipulated to determine the influence of hydrogel composition on the 
equilibrium degree of swelling, modulus of elasticity in compression, and on the rate of 
degradation of Network B.  To mimic the conditions in the gastrointestinal tract, 
properties of the hydrogels were evaluated after abrupt change of pH from pH 2.0 to pH 
7.4. The analysis of IPN structure revealed that crosslinking efficiency of radically 
polymerized Network B (10-30%) was lower than that of step polyaddition Network A.  
In the IPN gels, the crosslinking efficiency was even lower and was close to 10%.  
Factors contributing to the low crosslinking efficiency of IPN include higher dilution at 
network formation and possible negative effect of the components of Network A on 
radical polymerization of Network B.  The major advantage of IPN hydrogels, when 
compared to traditional pH-sensitive networks, is the linear swelling profile following 
abrupt change of pH from 2 to 7.4.  This indicates the potential of IPNs as carriers for 
oral drug delivery. 
5.2. Specific Aim 2. Design and Evaluation of a Targeted  
HPMA-Copolymer 
Targeting is one of the primary considerations in designing a specific and efficient 
drug delivery system. Here, a colon cancer-specific targeted polymeric drug delivery 
carrier was developed by conjugating a cyclic constrained nonapeptide into the water-
soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer.  HPMA copolymer-
RPM1 conjugate was prepared by binding of RPM1 to an HPMA copolymer precursor 




HPMA and N-methacryloylaminopropyl fluorescein thiourea (MA-FITC) to produce an 
HPMA copolymer-RPM2 conjugate.   
The impact of the structure of the HPMA copolymer-peptide conjugates on the 
biorecognition by poorly differentiated HT-29 colon carcinoma cells was investigated.  
The binding to and internalization by HT-29 cells were visualized by a radioiodination 
assay, flow cytometry, and confocal fluorescence microscopy.  The free peptide RPM3 
and HPMA copolymer-RPM1 and HPMA copolymer-RPM2 conjugates possessed low 
binding affinities; the Kd was in the 10-4 M range.  However, flow cytometry data 
demonstrated clear shifts in fluorescence profiles when comparing control polymers, 
P(H)-FITC and P(L)-FITC, with corresponding HPMA copolymer conjugates containing 
peptides RPM1 or RPM2.  Confocal fluorescence data clearly indicated a faster 
internalization of RPM3 when compared to a nonspecific sequence (NSP).  
5.3. Specific Aim 3. In Vivo Evaluation of Novel Colon Cancer 
Targeted HPMA-9-Aminocamptothecin 
A major challenge in cancer chemotherapy is the selective delivery of small 
molecule anticancer agents to tumor cells. Water-soluble polymer-drug conjugates 
exhibit good water solubility, increased halflife, and potent antitumor effects. By 
localizing the drug at the desired site of action, macromolecular therapeutics have 
improved efficacy and enhanced safety at lower doses. In this study, two novel, linear 
polymeric-systems were designed, one for systemic and the other for local delivery.  The 
former system was a carrier composed of N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymer, 9-aminocamptothecin (9-AC), and biorecognizable cyclic nonapeptide. The 




linker, namely an oligopeptide spacer glycylphenylalanylleucylglycyl (GFLG) and a self-
eliminating 4-aminobenzyl alcohol structure. In the latter system, a copolymer of HPMA 
and 9-aminocamptothecin bound via an aromatic azo bond and a self-elimination spacer 
was synthesized. 
Since small molecule drugs and macromolecular drugs enter cells by different 
pathways, multidrug resistance (MDR) can be minimized. Therapeutic efficiency of a 
systemic versus local approach was also evaluated in vivo using a noninvasive 
bioluminescence imaging tumor model. To this end, six groups were compared: a) 
untreated, b) free drug (oral), c) P-AZO-9-AC (oral), d) P-GFLG-9-AC (i.v.), e) P-GFLF-
9-AC-minPEG-RPM (i.v.), f) combination of P-GFLG-9-AC (i.v) and P-AZO-9-AC 
(oral). Mice treated with the polymer conjugates containing 9-AC or free drug had 
significantly longer tumor growth delay compared to untreated controls. Polymer 
conjugates given systemically performed slightly better than the conjugates given orally. 
However, there was no difference in the therapeutic effects among the targeted or 
untargeted conjugates. 
5.4. Future Work 
 Studies outlined in this thesis tried to investigate novel drug delivery strategies to 
reduce the nonspecific toxicities of conventional chemotherapeutics. Optimization of the 
binding affinity and due to the recent advances in cancer biology, selecting new targets 
can potentially increase the specificity of the delivery systems. Hence, the future work 





5.4.1. Optimization of RPM Peptide Sequence 
 High-affinity and high-specificity peptide can be potentially derived from the 
cyclic constrained nonapeptide, KPIEDRPME, by optimizing the sequence of the non- 
essential amino acids present (1). The first and last amino acids of this sequence are 
required for the cyclization process, and the RPM motif is essential for the 
biorecognition. Hence, the four amino acids flanking the RPM sequence can be altered to 
select peptides with a superior binding affinity. A combinatorial approach can be very 
advantageous in deriving novel sequences using a biased library (2, 3).    
5.4.3. In Vivo Studies 
The data for the preliminary in vivo experiments can be used to design two 
additional experiments. First, a dose escalation study can be performed to optimize the 
therapeutic regiment. Second, biodistribution studies can be used to determine the 
efficacy of the targeted HPMA conjugates to localize preferentially within the solid 
tumor.  
5.4.2. Selective Targeting of Cancer Stem Cells 
Conventional targeted therapies have been designed largely to target receptors 
that are overexpressed on the majority of tumor cells. While these therapies target and 
kill differentiated tumor cells, they spare a subset of population termed cancer stem cells 
(CSCs). Current advances in cancer stem cell biology suggest this subset of cells has the 
capacity to initiate tumors and possess therapeutic resistance (4, 5). This leads to the 
failure of current therapeutics to cure most cancer.  
Al-Hajj et al. (6) was one of the first groups to identify cancer stem cells in solid 




5.1). Hence, novel therapeutic agents can be designed to target this subset of population. 
Markers like CD44 and CD133+ (activated leukocyte cell adhesion molecule) are 
differentially expressed markers on the colon cancer stem cell (7, 8).  Hence, antibodies 





























Table 5.1 List of Tumor Stem Cell Markers 
Cancer/tumor type Markers Reference 
Breast CD44+CD24−/low, CK+, Hedgehog 
components 
(9-11) 
Prostate c-myc, beta-catenin, CD44(+), D133(+), 
ABCG2, Androgen receptor, 
CD44+/alpha2beta1hi 
(12-16) 
Colorectal EpCAM, CD44, CD166 (7, 8, 17) 
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